 
 
 
 
 
 
 
 
 
HOWARD FELDMAN, MDCM, FRCP(C)  
PROFESSOR, DEPARTMENT OF NEUROSCIENCES 
DIRECTOR, ALZHEIMER’S DISEASE COOPERATIVE STUDY (ADCS)  
DEAN, ALZHEIMER’S DISEASE AND NEURODEGENERATIVE RESEARCH  
[ADDRESS_544561]     La Jolla, [LOCATION_004] [ZIP_CODE] -0949     TEL: (858) 246- 1347   FAX: (858 ) 246-1414   
 
 
 
 
 
 
Protocol Title:  
Therapeutic Effects of Exercise in Adults with  
Amnestic Mild Cognitive Impairment  
 
Protocol Short Title:  EXERT  
 
Protocol Number:  ADC- 041-EX 
 
[STUDY_ID_REMOVED]  
 
Protocol  Version 7.0  
18NOV2021  
 
 
 
 

ADC-041-EX   Page 1 of 78 
 
 Version 7.0: 18NOV2021 
   
  
  
 
 
 
Protocol Title:  
 
Therapeutic Effects of Exercise in Adults with 
Amnestic Mild Cognitive Impairment  
  
Protocol Short Title:  
 
EXERT 
   
Protocol Number : 
 
ADC-041-EX  
 
Protocol Version 7.0 
18NOV 2021  
 
 
 
 Confidentiality Statement : 
The information in this document is privileged or confidential and may not be disclosed unless such disclosure is required by [CONTACT_774].  It is the property of NIH and 
ADCS and should not be copi[INVESTIGATOR_430494].  Persons 
to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by [CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you, which is indicated as privileged or 
confidential. Any unauthorized review, use, disclosure, copying or distribution is strictly 
prohibited.   

ADC-041-EX   Page 2 of 78 
 
 Version 7.0: 18NOV2021 
   
 SIGNATURE [CONTACT_1783]  
 
(SIGNATURES ON FILE AT ADCS)  
 
 
  ____________________________________  ___________________ 
Laura Baker, PhD       Date (MM/DD/YYYY)  
Project Director Professor of Internal  Medicine - Geriatrics  
Wake Forest University  School of Medicine  
  
 
 ____________________________________  ___________________ 
Carl Cotman, PhD       Date (MM/DD/YYYY)  
Project Director Professor of Neurology & Neurobiology  
University of [LOCATION_004], Irvine    
 
____________________________________  ___________________ 
Howard Feldman, MDCM, FRCP(C)     Date (MM/DD/YYYY)  
Principal Investigator  
[CONTACT_7351]’s Disease Cooperative Study  
University of [LOCATION_004], San Diego    
 
____________________________________  ___________________ 
Gabriel Leger , MD       Date (MM/DD/YYYY)  
Medical Monitor  
Alzheimer's Disease Cooperative Study  
University of [LOCATION_004], San Diego   
ADC-041-EX   Page 3 of 78 
 
 Version 7.0: 18NOV2021 
   
 Sponsor:  
 Laurie M. Ryan, PhD  
National Institute on Aging 
[ADDRESS_544562] Bethesda, MD [ZIP_CODE] 
[EMAIL_8198]  
Tel: [PHONE_8954]  
 
Protocol Number:   
ADC -041-EX 
 
Project Directors: 
 
   
  
Laura Baker, PhD 
Wake Forest University Health Sciences  
Medical Center Boulevard Winston Salem, NC  [ZIP_CODE] 
[EMAIL_8199] 
Tel: 336-713 -8831 
 
Carl Cotman, PhD University of [LOCATION_004] - Irvine 
School of Medicine  
1113 Gillespie Building  
Irvine, CA  [ZIP_CODE] [EMAIL_8200]  
Tel: 949 -824-5847  
 
Principal Investigator, Coordination & Data  
Management Center Coordinating Center :  
Howard Feldman, MD  
ADCS Director  
Alzheimer’s Disease Cooperative Study  
University of [LOCATION_004], San Diego [ADDRESS_544563]  
La Jolla, CA [ZIP_CODE] [EMAIL_8201]
 
Tel: (858) 246 -1365  
 
Medical Emergencies:   
Gabriel Leger , MD  
Medical Monitor  
Alzheimer’s Disease Cooperative Study  
[EMAIL_8202]  
Tel: (858)  246-2539 
 
 
Version:                        
7.0 18NOV 2021  
 
ADC-041-EX   Page 4 of 78 
 
 Version 7.0: 18NOV2021 
   
 TABLE OF CONTENTS  
 
LIST OF ABBREVIATIONS  ......................................................................................................... 9 
PROTOCOL SYNOPSIS ............................................................................................................ 11 
1.0 INTRODUCTION  ........................................................................................................... 13 
 Primary Aim  .................................................................................................................... 13 
 Secondary Aims  ............................................................................................................. 14 
2.0 Preliminary Studies ..................................................................................................... 15 
 Summary of Clinical Findings  ......................................................................................... 15 
 Safety and Compliance .................................................................................................. 16 
3.0 Background and significance ..................................................................................... 16 
 Rationale for Aerobic Exercise as a Therapeutic Intervention in Mild Cognitive 
Impairment  ..................................................................................................................... 16 
 Rationale for Aerobic Exercise Effects on AD Pathology in the Brain ............................ 17 
 Rationale Supporting Selection of Primary and Secondary Cognitive Outcomes  .......... 17 
 Rationale for Length and Design of EXERT  ................................................................... 18 
 Rationale for Population Selection  ................................................................................. 18 
 Rationale for Selected Exercise Dose ............................................................................ 18 
 Rationale for Intervention Implementation in Community -Based Facilities  .................... 18 
 Rationale for Magnetic Resonance Imaging .................................................................. 19 
 Rationale for Inclusion of Actigraphy  .............................................................................. 19 
 Rationale for Collection of Bioflui ds ............................................................................... 20 
4.0 Potential Risks and benefits associated with Intervention ..................................... 20 
 Potential Benefits  ........................................................................................................... 20 
 Potential Risks  ............................................................................................................... 20 
5.0 Sample Size and Statistical Plan ................................................................................ 22 
 Randomization ............................................................................................................... 22 
 Power and Sample Size Determination ......................................................................... 22 
 Selection of Participants to be Used in Analysis  ............................................................ 23 
 Efficacy Analysis  ............................................................................................................ 23 
5.4.1 Analysis of Primary Outcome ....................................................................................... 23 
5.4.2 Analyses of Secondary Outcomes  ............................................................................... 24 
 Safety Analysis  ............................................................................................................... 25 
 Termination of the Trial  .................................................................................................. 25 
ADC-041-EX   Page 5 of 78 
 
 Version 7.0: 18NOV2021 
   
 6.0 Interventions and implementation ............................................................................. 25 
 Overview  ........................................................................................................................ 25 
 Collaboration with the YMCA  ......................................................................................... 26 
6.2.1 YMCA Study Team ....................................................................................................... 26 
6.2.2 Interface Between the Clinic and the YMCA  ................................................................ 27 
6.2.3 Adverse Event Reporting by [CONTACT_430550] ............................................................... 27 
 Implementation of the Interventions  ............................................................................... 28 
6.3.1 Aerobic Training Intervention ....................................................................................... 30 
6.3.2 Stretching, Balance, and Range of Motion Intervention ............................................... 31 
 Adherence ...................................................................................................................... 31 
 Safety During Exercise ................................................................................................... 32 
 Temporary Intervention Discontinuation ........................................................................ 33 
 Reasons for Temporary Discontinuation ........................................................................ 33 
 Timing of Temporary Discontinuation Relative to Assessment of Primary and Secondary 
Outcomes  ...................................................................................................................... 34 
 Blinding  .......................................................................................................................... 34 
 Breaking the Blind .......................................................................................................... 35 
 Concomitant AD Medications  ......................................................................................... 35 
7.0 Study Population ......................................................................................................... 35 
 Inclus ion Criteria ............................................................................................................ 35 
 Exclusion Criteria  ........................................................................................................... 36 
 Recruitment and Retention Strategies  ........................................................................... 38 
 Inclusion of Women and Minorities ................................................................................ 38 
8.0 Study Timeline ............................................................................................................. 38 
9.0 Description of study visits .......................................................................................... 38 
 Screening I (Visit 0)  ........................................................................................................ 38 
 Screening II (Visit 1)  ....................................................................................................... 39 
 Baseline (Visit 2)  ............................................................................................................ 40 
 Month 6 (Visit 3)  ............................................................................................................. 42 
 Month 12 (Visit 4) / or Early Termination ........................................................................ 43 
 Month 18 (Visit 5)  ........................................................................................................... 45 
10.0 Early intervention discontinuation ............................................................................. 46 
 Reasons for Early Discontinuation  ................................................................................. 47 
ADC-041-EX   Page 6 of 78 
 
 Version 7.0: 18NOV2021 
   
 11.[ADDRESS_544564]  ...................................................................................... 48 
11.2.4 ADAS- Cog-Exec Global Composite ............................................................................. 48 
11.2.5 Executive Function Composite ..................................................................................... 49 
11.2.6 Epi[INVESTIGATOR_430495]  ........................................................................................ 51 
 Behavioral and Functional Evaluations  .......................................................................... 51 
11.3.1 Clinical Dementia Rating Scale – Sum of Boxes (described above)  ............................ 51 
11.3.2 ADCS -Activities of Daily Living-MCI  ............................................................................. 51 
11.3.3 Behavior Rating Inventory of Executive Function – Adult Version ............................... [ADDRESS_544565] .............................................................................................. 54 
12.0 Study– specific procedures ......................................................................................... 54 
 Safety Assessments  ....................................................................................................... 54 
12.1.1 Physical and Neurological Examination ....................................................................... 55 
12.1.2 Electrocardiogram  ........................................................................................................ 55 
12.1.3 Clinical Laboratory Evaluations  .................................................................................... 55 
ADC-041-EX   Page 7 of 78 
 
 Version 7.0: 18NOV2021 
   
 
 Biofluids  .......................................................................................................................... [ADDRESS_544566] ............................................................................................................ 58 
 Actigraphy Recordings  ................................................................................................... 59 
13.0 Personnel Requirements ............................................................................................ 59 
 Clinic Personnel  ............................................................................................................. 59 
 YMCA Study Team (see  Section 6.2.1) ......................................................................... [ADDRESS_544567] ............................................................................. 63 
17.0 Recording and collection of data ............................................................................... 63 
 Case Report Form  .......................................................................................................... 63 
 Audio / Visual Recording ................................................................................................ [ADDRESS_544568] .............................................................................................. 65 
 Informed Consent and HIPAA Compliance  .................................................................... 65 
18.3.1 Participant Confidentiality | HIPAA  ............................................................................... 66 
 Genetic Research and Storage of Genetic Material  ....................................................... 66 
 Storage of Biospecimen Samples  .................................................................................. 66 
 MRI Data Storage .......................................................................................................... 67 
ADC-041-EX   Page 8 of 78 
 
 Version 7.0: 18NOV2021 
   
 
 Inclusion of Children as Participants in Research Involving Human Subjects  ............... [ADDRESS_544569] Retention ......................................................................................................... 67 
21.0 Publication Policy  ........................................................................................................ 68 
22.0 Sharing of Final Research Data  .................................................................................. 68 
23.0 Literature Cited ............................................................................................................ 69 
Appendix 1: Schedule of Events ............................................................................................. 77 
  
ADC-041-EX   Page 9 of 78 
 
 Version 7.0: 18NOV2021 
   
 LIST OF ABBREVIATIONS  
 
3MSE  Modified Mental Status Exam  
Aβ Beta -Amyloid  
AD Alzheimer’s D isease  
ADAS -Cog Alzheimer’s Disease Assessment Scale – Cognitive Subscale  
ADAS -Cog-Exec  Alzheimer’s Disease Assessment Scale – Cognitive and Executive 
Function Composite Score  
ADCS  Alzheimer’s Disease Cooperative Study  
ADCS -ADL-MCI Alzheimer’s Disease Cooperative Study – Activities Of Daily Living – 
Mild Cognitive Impairment  
ADNI  Alzheimer’s Disease Neuroimaging Initiative  
AE Adverse E vent 
APOE/APOE4 Apolipoprotein /Apolipoprotein  Epsilon [ADDRESS_544570]  
AX Aerobic E xercise  
BDNF  Brain -Derived Neurotrophic F actor  
BRIEF -A Behavior Rating Inventory Of Executive Function – Adult Version  
BPSO  Behavioral Pattern Separation Of Objects (Stark Task)  
CDR  Clinical Dementia Rating  
CDR -SB Clinical Dementia Rating – Sum Of Boxes  
CFR Code Of Federal Regulations  
CRF/e -CRF Case Report Form/Electronic Case Report Form  
CSF Cerebrospi[INVESTIGATOR_1304] F luid 
DET Detection Task (Cogstate)  
DCCS  Dimensional Change Card Sort (NIH Toolbox)  
DNA  Deoxyribonucleic A cid 
DSMB  Data And Safety Monitoring Board  
DSST  Digit Symbol Substitution Test  
ECG  Electrocardiogram  
EDC  Electronic Data Capture  
EQ5D  EuroQol [ADDRESS_544571] (Cogstate)  
HBA1C Hemoglobin A1c  
HCY  Homocysteine  
HIPAA  Health Insurance Portability And Accountability Act  
HR Heart R ate 
ADC-041-EX   Page 10 of 78 
 
 Version 7.0: 18NOV2021 
   
 HRR  Heart Rate R eserve  
ICF Informed Consent Form  
ICH International Conference On Harmonisation  
IDN Identification Task (Cogstate)  
IRB Institutional Review Board  
LP Lumbar P uncture  
MCI Mild Cognitive I mpairment  
MEDDRA  Medical  Diction ary For Regulatory Activities  
MMA  Methylmalonic A cid 
MMRM  Mixed Effects Model For Repeated Measures  
MMSE  Mini-Mental State Examination  
MPRAGE  Magnetization Prepared Rapid Gradient Echo  
MR/MRI  Magnetic Resonance / Magnetic Resonance Imaging  
NIA Nation al Institute On Aging  
NIH National Institutes Of Health  
NPI [INVESTIGATOR_430496]-Steroidal Anti -Inflammatory Drugs  
OBK  One Back Task (Cogstate)  
OCL  One Card Learning (Cogstate)  
OHRP  Office For Human Research Protections  
PD Project Di rector  
PCP Primary Care Provider  
PHI Protected Health I nformation  
PI [INVESTIGATOR_430497] N umber  
RPE Rating Of Perceived Exertion  
PT Prothrombin T ime  
PTT Partial Thromboplastin T ime  
SAE Severe Adverse E vent 
SBR Stretching/Balance/Range Of M otion  
SD Standard D eviation  
SF-36 36-Item Short Form Health Survey  
sMRI Structural  Magnetic Resonance Imaging  
T Tesla  
TAPA  Telephone Assessment Of Physical Activity  
TEAE  Treatment -Emergent Adverse E vent 
TSH Thyroid Stimu lating H ormone  
VEGF  Vascular Endothelial Growth F actor  
WAIS -R Wechsler Adult Intelligence Scale – Revised  
Y-PM YMCA Project Manager  
Y-[LOCATION_003]  YMCA Of The [LOCATION_002] Of America  
  
ADC-041-EX   Page 11 of 78 
 
 Version 7.0: 18NOV2021 
   
 PROTOCOL SYNOPSIS 
PROTOCOL TITLE 
   Therapeutic Effects of Exercise in Ad ults with  
Amnestic Mild Cognitive Impairment  
PROJECT DIRECTORS  Laura Baker, PhD  and Carl Cotman, PhD  
STUDY SPONSOR  National Institute on Aging  (NIA)  
STUDY DESIGN   Phase 3 , multicenter, randomized single -blind study to examine the 
effects of aerobic exercise on cognition, functional status, whole 
and regional brain atrophy, whole and regional cerebral blood flow, 
and cerebrospi[INVESTIGATOR_430498]’s disease in 300 
adults with amnestic mild cognitive impairment (MCI)  
DURATION OF STUDY 
PARTI CIPATION  • Screening period of up to 4 weeks  
• Supervised intervention duration of 12 months  
• Unsupervised intervention extension of 6 months  
SUMMARY OF 
INVESTIGATIONAL 
INTERVENTION  • Two interventions will be implemented: supervised and 
structured moderate/high intensity aerobic training vs. 
stretching/balance/range of motion for 12 months, followed by a 
6-month unsupervised extension 
• Moderate/high intensity aerobic exercise will involve training at 
70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm -up and 5 minutes for cool -down, 4 times per 
week, for 12 months while supervised twice per week by a 
study -certified YMCA Trainer; participants in the 
stretching/balance/range of motion group will adhere to the 
same timeline, but exercise at an intensity at or below 35% 
heart rate reserve  
SUMMARY OF KEY 
ELIGIBILITY CRITERIA  • Age: 65 to 89 years (inclusive)  
• Mini-Mental State Examination at screening: ≥24 for 
participants with 13 or more years of education; ≥ 22 for 
participants with 12 or fewer years of education  
• Clinical Dementia Rating = 0.5 with a memory score of 0.5 or 
greater  at screening 
• Profile of test scores and clinical ratings is consistent with 
amnestic mild cognitive impairment  
• Modified Hachinski score ≤4 
PRIMARY OUTCOME 
MEASURE  
 ADAS-Cog-Exec Global Composite Score: Word Recall, Delayed 
Word Recall, Orientation and Number Cancellation subscales of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale, 
version 13 (ADAS- Cog13); tests of executive function including 
Trail-Makin g Test A and B, Digit Symbol  Substitution Test, and 
Category  Fluency ; and Clinical Dementia Rating (CDR) sum of box 
scores for Memory, Orientation and Judgement and Problem 
Solving.  
ADC-041-EX   Page 12 of 78 
 
 Version 7.0: 18NOV2021 
   
 SECONDARY OUTCOME 
MEASURES  Clinical Dementia Rating – Sum of Boxes , ADAS -Cog13  total 
score , Executive Function Composite, Epi[INVESTIGATOR_430499], functional status ( Alzheimer’s Disease Cooperative 
Study – Activities Of Daily Living – MCI, Behavior Rating Inventory 
Of Executive Function – Adult Version),  mood and health-rela ted 
quality of life  (Neuropsychiatric Inventory , 36-Item Short Form 
Health Survey , EuroQol 5-Item Health Questionnaire) , brain 
volume and perfusion using structural  and functional magnetic 
resonance imaging, biomarkers in blood and cerebrospi[INVESTIGATOR_872], 
actigraph y-measured  total activity and sleep integrity  
  
ADC-041-EX   Page 13 of 78 
 
 Version 7.0: 18NOV2021 
   
 1.0 INTRODUCTION  
 
An urgent need exists to find effective treatments for Alzheimer’s disease (AD)  that can arrest or 
reverse the disease at its earliest stages. The emotional and financial burden of AD to patients, 
family members, and society is enormous, and is predicted to grow exponentially as the median 
population age increases. Amnestic mild cognitive impairment (MCI), characterized by [CONTACT_430551], is presumed early stage AD, 
and the prodrome of clinical dementia. The potential to preserve, or even enhance, cognition in adults at high risk of cognitive decline due to neurodegenerative disease clearly has important implications not only for the affected individual, but also for the support system that bears the social and financial burdens of long-term caregiving. However, prior studies testing interventions to prevent or arrest cognitive decline in MCI using a variety of different pharmaceutical approaches have been largely negative. Contemporary approaches in modern health care are beginning to acknowledge lifestyle modification as a potential potent health-promoting and 
disease-modifying strategy to preserve or improve cognitive function and quality of life for older 
adults. The long prodromal period associated with MCI provides an ideal opportunity for lifestyle interventions such as increased physical activity to protect and enhance cognition when neuropathologic processes that cause decline can still be prevented or delayed.   To date, no large multi -site study has been carried out to evaluate potential therapeutic effects 
of aerobic exercise on brain function and markers of disease progression in adults with MCI and 
thus at high risk for dementia despi[INVESTIGATOR_430500]. This pi[INVESTIGATOR_430501]-to-high intensity aerobic 
exercise can improve cognition and other measures of brain health in adults with MCI. If 
successful, the results of this study may have large-scale implications for public policy regarding 
standard of clinical care and prescriptive practices for a fast-growing and vulnerable population of older adults. The study will also provide information about potenti al mechanisms through 
which aerobic exercise may benefit brain function by [CONTACT_430552][INVESTIGATOR_872] (CSF). These results will likely have 
considerable clinical , scientific , and social  significanc e, and may provide therapeutically  relevant 
knowledge about the effect of aerobic exercise on AD pathophysiology. 
 
 Primary Aim  
 
Aim 1:  To test the hypothesis  that 12 months of supervised moderate/high intensity 
aerobic exercise, relative to a stretching/balance/range of motion control , will improve 
cognitive function, measured using a validated composite score (ADAS-Cog -Exec) that 
includes select subscales (Word Recall, Delayed Word Recall, Orientation, Number Cancellation)  from the Alzheimer’s Disease Assessment Scale – Cognitive Subscale 
(version 13); tests of executive function including Trail -Making Test A and B,  Digit 
Symbol  Substitution Test, Category  Fluency; and Clinical Dementia Rating (CDR) sum 
of box scores for Memory, Orientation and Judgement and Problem Solving in older 
adults with amnestic MCI. 
 
ADC-041-EX   Page 14 of 78 
 
 Version 7.0: 18NOV2021 
   
 
 Secondary Aims 
 
Aim 2 : To test the hypothesis that 12 months of aerobic exercise, relative to the control , 
will reduce clinical ratings of cognitive impairment as measured by [CONTACT_430553] – Sum of Boxes, and total score on the ADAS- Cog13.  
 
Aim 3: To test the hypothesis that 12 months of aerobic exercise, relative to the control , 
will improve executive function and epi[INVESTIGATOR_10682], as measured by [CONTACT_121982]-specific 
composite scores derived from ADAS -Cog -Exec subtests and other computer -
administered tests (Cogstate, NIH Toolbox) .  
 Aim 4: To test the hypothesis that 12 months of aerobic exercise, relative to the control , 
will improve daily living  skills ( ADCS –Activities Of Daily Living –MCI, Behavior Rating 
Inventory Of Executive Function– Adult Version), mood and health-related quality of life 
(Neuropsychiatric Inventory , 36-Item Short Form Health Survey, EuroQol 5-Item Health 
Questionnaire), and subjective memory concerns (Cognitive Change Index ).  
 
Aim 5: To test the hypothesis that 12  months of aerobic exercise, relative to the control, 
reduces the rate of regional and whole brain atrophy, and increases regional and whole 
brain perfusion assessed using volumetric and functional magnetic resonance imaging 
(fMRI) . 
 Aim 6: To test the hypothesis that [ADDRESS_544572] 
exploratory analyses of exercise effects on other  markers of brain health and disease in 
CSF and blood (e.g., brain-derived neurotrophic factor , vascular endothelial growth 
factor , measures of inflammation, proteomics/metabolomics ). 
 Aim 7: To examine whether gender, age, baseline AD biomarker profile, a polipoprotein 
epsilon 4 (ApoE4)  genotypes, total activity, and sleep integrity  predict treatment 
response.  
 
Aim 8: To examine the enduring cognitive and behavioral  effects of the intervention 
following a [ADDRESS_544573] a model for a community -based exercise prescription in  adults with 
MCI.  
 
Aim 9 : To assess the impact of the intervention on the study partner’s health, wellbeing 
and quality of life using the Study Partner Self-Assessment Questionnaire.  
 
  
ADC-041-EX   Page 15 of 78 
 
 Version 7.0: 18NOV2021 
   
 2.[ADDRESS_544574] 
old.8 
 Exercise benefits on cognition are also supported by [CONTACT_430554]. The results of a meta-analysis support an overall benefit of aerobic exercise on epi[INVESTIGATOR_6368], attention, processing speed, and executive function in non-demented older adults.
9 
Short-term aerobic training (e.g., 4-1 2 months) increases whole brain and hippocampal volume, 
and regional gray and white matter volumes in prefrontal cortex.10,[ADDRESS_544575]-intervention connectivity exceeded that observed in young adults, and the primary circuit altered by [CONTACT_430555], an important region for executive control. Positive effects of exercise on resting network activity within the frontal lobe and 
between frontal, posterior parietal, and temporal cortices (default mode network) are al so 
reported by [CONTACT_2312].
[ADDRESS_544576] of aerobic exercise on brain structure and function in adults with amnestic MCI has only recently 
been examined. Conceivably, exercise may not confer the same benefits when brain health is compromised by [CONTACT_430556]. However, in adults with AD, improved cardiorespi[INVESTIGATOR_430502].
14 In adults with MCI and presumably 
relatively less AD pathology, increasing fitness is associated with less regional brain atrophy in 
medial temporal (including entorhinal) cortex.[ADDRESS_544577] been completed to date, the results thus far provide encouraging support for cognition-enhancing effects. In the Baker et al. controlled 6- month pi[INVESTIGATOR_430503] , they reported positive effects of exercise on 
cognition, particularly on tasks of executive function.
16 Favorable exercise effects on 
glucoregulation and Aβ levels in plasma were also reported. In a larger controlled 6-month trial 
of home-based aerobic exercise (walking) versus usual care in adults with MCI, Lautenschlager et al.
[ADDRESS_544578] of cognitive function (ADAS -Cog), on delayed 
word list recall, and on a clinician-based assessment, with evidence for persisting benefits at the 
ADC-041-EX   Page 16 of 78 
 
 Version 7.0: 18NOV2021 
   
 18-month follow -up. These studies are encouraging, but not without limitations. In the 
Lautenschlager study, the interventions were not tightly controlled (usual care group was 
permitted to exercise), and cognitive abilities that typi[INVESTIGATOR_430504]. In the Baker et al. study, sample size was small. 
Biomarkers in brain were not collected in either study.  
 In a recent larger 6-month study  in MCI that included brain imaging and CSF collection,
18 
moderate/high i ntensity aerobi c exercise vs. stretching improved executive function; increased 
blood flow in areas of the brain that are characteristically reduced with aging and with progression of AD; and reduced CSF levels of phosphorylated tau protein – a hallmark 
biomarker of disease progression. The multi -site trial  of exercise in adults with MCI, referred to 
as “EXERT ,” will test whether these promising findings can be confirmed in a larger and longer 
duration study to definitively establish the therapeutic efficacy of moderate/high intensity aerobic exercise to slow disease progression in  older adults at high risk for AD dementia.   
 
 Safety and Compliance 
 
Aerobic exercise, at the intensity targeted in EXERT, is well-tolerated even in sedentary older 
adults, is the standard recommendation by [CONTACT_430557],19 
and is commonly used in community settings to improve physical fitness. Although aerobic exercise intensity in EXERT is described as ‘moderate/high’, this descriptor in no way describes 
intensity of exercise completed by [CONTACT_430558]. Moderate/high intensity of aerobic exercise in EXERT is defined as 70 -80% of heart rate reserve ( HRR), which is similar to 70-80% 
of maximum heart rate (HR) with an adjustment for baseline cardiorespi[INVESTIGATOR_17863]. This 
exercise intensity was successfully achieved in three 6-month studies conducted by [CONTACT_430559]. that enrolled over 130 older adults who were at increased risk for AD dementia. In these 
studies, serious adverse event (SAE) rates were low (<5%) and comparable across intervention 
groups.
16,18,20  
 
3.0 BACKGROUND AND SIGNI FICANCE  
 
 Rationale for Aerobic Exercise as a Therapeutic Intervention in M ild C ognitive 
Impairment   
 
The study rationale is based on growing evidence that aerobic exercise has numerous health-
restoring effects in the brain, and that a sedentary lifestyle may contribute to AD pathogenesi s.
21,22 Increased physical activity improves cardiovascular health, glucose 
regulation, and lipid metabolism, and has positive effects on mood and stress in older adults .23 
In clinical studies, aerobic exercise is associated with improved cognitive function,16,18 increased 
brain volume,10,11 increased brain perfusion,18 and reduced levels of AD biomarkers in CSF .18,22 
 
  
ADC-041-EX   Page 17 of 78 
 
 Version 7.0: 18NOV2021 
   
 
 Rationale for Aerobic Exercise Effects on AD Pathology in the Brain 
 
The identification of biomarkers associated with AD pathogenesis can aid diagnosis, help to monitor disease progression, and identify potential underlying mechanisms. Thus, exercise-
induced effects on AD biomarkers represent a key component of this trial. EXERT will examine 
whole brain and regional changes in structure and blood flow as measured by [CONTACT_430560] (MRI), and chemical biomarkers in CSF  and blood. Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) studies provide valuable longitudinal MRI data in adults with MCI and early stage dementia versus healthy adults pointing to entorhinal and hippocampal atrophy as sensitive markers of disease progression.
24,25 New evidence also suggests that aerobic 
exercise may reverse aging- and AD -related changes in cerebral blood flow.18 CSF 
concentration of beta-amyloid ( Aβ) 1-42 (Aβ42 ), the more toxic form of the Aβ peptide, is also 
an important marker of AD risk.25-28 A decrease in CSF Aβ42 is an early event preceding 
hippocampal atrophy, tauopathy, and other degenerative processes,29,30 and thus a valuable 
index of disease progression.  
 Although reducing rate of progression from MCI to Alzheimer ’s dementia is not a primary  
outcome in this study, the use of progression-sensitive biomarkers will be a powerful tool to evaluate the impact of exercise on brain health, and on disease progression in future studies. In cross-sectional studies, high-levels of physical activity are associated with reduced cerebral Aβ deposition (evaluated with brain imaging using positron emission tomography) and increased CSF Aβ in older adults,
22 and in a controlled 12- month trial of moderate-intensity aerobic 
exercise, hippocampal volume in older adults was increased by 2%, reversing age-rela ted loss 
by 1-2 years.31 Similar aging- and AD -related markers of brain structure and function will be 
measured to provide important information about mechanisms that may account for positive 
exercise effects, including CSF levels of inflammatory markers such as IL-1β, IL-6, IL-8, TNFα,32 
about proteolytic products such as visinin-like protein-1 (a marker of neuronal injury),33 and 
about growth factors such as brain- derived neurotrophic factor ( BDNF ).34,35 In animal studies, 
exercise increases brain BDNF, reduces peripheral and brain inflammation, and slows progression of neurodegeneration.
36,37 Other new markers that probe possible mechanisms are 
emerging though the use of proteomics  and metabolomics , which will be explored in EXERT.38-
41 Genotype effects on response to exercise will also be examined, including the ε4 allelic 
variant of the apolipoprotein E (ApoE) gene that has independent and synergistic effects on Aβ -
related AD pathogenesis, atherosclerotic changes, cardiovascular disease, and cognitive decline.
42-48  
 
 Rationale Supporting Selection of Primary and Secondary Cognitive Outcomes 
 
Recent findings  from ADNI indicate that ADAS -Cog scores reliably change over 12 months in 
MCI. A modified version of the ADAS -Cog  (version 13) supplemented with other tests, referred 
to as ADAS- Cog-Exec, has been validated49 and will be used as the primary outcome measure 
to assess efficacy in EXERT. This composite includes  ADAS-Cog 13 subtests shown to be 
maximally sensitive to change over time in MCI (Word Recall, Delayed Word Recall, Orientation, Number Cancellation), additional  measures of executive function (Trail- Making 
ADC-041-EX   Page 18 of 78 
 
 Version 7.0: 18NOV2021 
   
 Test, Digit Symbol Substitution Test [ DSST] , Category  Fluency) , and Clinical Dementia Rating 
scale sum of box scores for Memory, Orientation, and Judgement and Problem Solving. 
Although inclusion of supplemental measures may increase variability overall, a heavier 
executive function load in the ADAS -Cog composite will likely ad d sensitivity given prior 
evidence of beneficial exercise effects on this cognitive domain. The selected secondary 
cognitive measures were either sensitive to aerobic exercise in previous studies of healthy older 
adults20,50,51 or individuals with MCI,16,18,20 or to early hippocampal/medial temporal cortical 
changes in MCI.52  
 
 Rationale for Length and Design of EXERT 
 
In preliminary studies, beneficial cognitive effects in MCI were  observed following 6 months of 
moderate/high intensity aerobic exercise. EXERT includes an extend ed intervention period of 
one year for the primary analyses, which should only increase power to detect a treatment effect 
on cognition and biomarker endpoints in  MCI. A 6-month unsupervised extension of the 
intervention will provide additional information regarding longer -term efficacy and exercise 
adherence that will provide important translational value for future c ommunity -based and, 
potentially , therapeutic  programs for adults with MCI.  
 
 Rationale for Population Selection 
 
Adults with a cognitive profile indicating amnestic MCI will be enrolled in EXERT to examine 
potential therapeutic effects on brain structure and function in early stage AD when neuropathologic processes that cause decline can still be potentially prevented or delayed. 
Although enrol lment will not be restricted to biomarker -positive patients, the trial will collect CSF 
biomarkers and MRI measures of atrophy  and blood flow that can be examined relative to 
treatment response and group assignment in secondary analyses.  
 
 Rationale for Se lected Exercise Dose  
 
The selected dose of aerobic exercise was based on previous work showing that the targeted 
frequency, duration, and intensity improved cognitive function both in healthy older 
adults10,11,31,51 and in MCI.16,18 Variability in achieved adherence for the aerobic training (AX) 
group will permit examination of relationships between exercise volume ( based on intensity, 
duration, frequency) and magnitude of cognitive and biomark er response. A maximum of 35%  
HRR is targeted in the stretching/balance/range of motion (SBR)  group as this level of exertion 
falls well below American College of Sports Medicine (ACSM) guidelines for moderate-intensity exercise
[ADDRESS_544579] the feasibility of prescriptive aerobic exercise for adults with MCI 
using community-based facilities equipped to successfully provide adequate resources and a 
structured system of social and safety support. The national office of the YMCA  (referred to as 
ADC-041-EX   Page 19 of 78 
 
 Version 7.0: 18NOV2021 
   
 Y-[LOCATION_003] ) and local YMCA branches will provide facilities for exercise and trainer supervision of 
participants as they complete their assigned intervention activities. The Y -[LOCATION_003] has worked 
closely with the study leadership to identify suitable YMCA facilities  near parti cipating clinic sites  
that will provide oversight of study -related activities carried out at the YMCAs, and ensure 
participant safety and high levels of intervention fidelity. This innovative collaboration between 
academia and a well -established national nonprofit community -based organization will test a 
highly translatable mechanism for delivery of a promising behavioral intervention to slow or 
prevent progression to Alzheimer’s dementia.     
 
 Rationale for Magnetic Resonance Imaging 
 Longitudinal data collected in ADNI provides robust evidence that structural MRI can be a 
credible predictor of future cognitive and functional decline, and is sensitive to total and hippocampal/entorhinal volume reductions over a 12-month period.
24,25,53 Jack et al. examined 
the role of structural MRI outcomes as endpoints for disease progression in therapeutic trials for AD and reported that multi -site consistency is feasible.
54 Others highlight particular vulnerability 
of the nearby [CONTACT_430561].55 The results of prior 
normal aging studies show  positive effects of exercise on hippocampal, prefrontal, and pos terior 
parietal regions ;10,11,[ADDRESS_544580] a neuropathologic signature: [CONTACT_430629] -dwelling older adults, brain Aβ burden was 
increased in older adults with self-reported shorter sleep duration and quality ,
[ADDRESS_544581] total quantity of other physical activity completed during other times of the day. Con trolled trials of structured exercise typi[INVESTIGATOR_430505]. The importance of objective measures of total 
physical activity is underscored by [CONTACT_430562]-041-EX   Page 20 of 78 
 
 Version 7.0: 18NOV2021 
   
 total physical activity predicts reduced dementia risk,64 and that older adults who engage in 
structured exercise may actually be less active at other times of the day .65 Controlled exercise 
trials that fail to quantify total physical activity may overlook  an important mediator of response 
to the intervention. 
 
 Rationale for C ollection of Bio fluids 
 
CSF b iomarkers  associated with AD pathology such as  Aβ42, Aβ 1-40 (Aβ 40) and total and 
phosphorylated tau protein will be measured, as will relevant biomarkers in blood. Residual 
specimens will be banked in the ADCS biospecimen bank  to permit putative and evolving 
biomarkers associated with AD pathology (such as brain-derived neurotrophic factor [BDNF ], 
vascular endothelial growth factor [VEGF], insulin, inflammatory markers ) to be examined 
later.66,[ADDRESS_544582] cognitive benefit may be seen in adults  with 
the ε4 allelic variant of the A poE genotype,68 recent data indicate that exercise may benefit ε4 
carriers and non-carriers alike . Specific Aim 7 will examine whether ApoE4 carriage is  a 
predictor of treatment response.  
 
4.0 POTENTIAL RISKS AND BENEFITS ASSOCIATED WITH INTERVENTION  
 
 Potential B enefits 
 
There is an urgent need to identify promising treatments for adults with MCI who are at 
increased risk for progression to Alzheimer’s dementia. At present, no large multi -site study has 
evaluated the potential therapeutic effect of [ADDRESS_544583] 12 months of the study . The relatively 
minor risks posed by [CONTACT_25234], cognitive testing, MRI and lumbar puncture ( LP) are 
outweighed by [CONTACT_430563].  
 
 Potential Risks  
 
Although regular physical activity and exercise have numerous health benefits on blood 
circulation, metabolism, lipoprotein profile, bone mass, risk of falling and disease,69 high-
intensity exercise can be associated with greater risk of adverse cardiovascular events,70 as 
ADC-041-EX   Page 21 of 78 
 
 Version 7.0: 18NOV2021 
   
 well as orthopedic71 and soft tissue (muscle, tendon, cartilage) injury. High-intensity exercise is 
also associated with lower adherence to a training regimen than lower -intensity exercise.72 
Evidence favoring high-intensity over moderate-intensity exercise, however, is provided by a 
recent joint report by [CONTACT_430564]73 showing greater risk 
reduction for cardiovascular disease and all -cause mortality. The EXERT protocols of 
moderate/ high intensity aerobic training are consistent with the latest ACSM exercise 
recommendations for older adults.[ADDRESS_544584] for overweight and unfit older 
adults.74 When sedentary adults begin to walk or jog, they may develop foot, leg, and knee 
injuries when training is performed more than 3 days per week and for more than 30 minutes per session;
75 while prolonged exercise may result in overuse-related orthopedic injuries.74 The 
EXERT protocol that includes gradual increments of exercise intensity and duration, under the 
supervision of a trainer  and taking into account individual needs and limitations, is in 
accordance with this recommendation and its safety has been established in other community -
based exercise programs.76-78 In previous pi[INVESTIGATOR_430506], of the 100 enrollees who completed the high-intensity arm (meeting all EXERT inclusion 
criteria),16,20,79 only 3  subjects (3%) were dropped due to a cardiovascular adverse event (AE) 
(follow -up tests indicated chronic disease pre-dating study entry  for all 3 adults ).  
 There are no known risks associated with participation in the SBR control group. 
 
[ADDRESS_544585] medical personnel in the event of a medical emergency. Also, institutional and community Emergency Medical Services (EMS) will be engaged (call 9 -1-1) if needed. 
 
Brain MRI. All participants will be screened for presence of iron-containing substances near the 
head that can be perturbed by [CONTACT_430565], including pacemakers, cardiac 
defibrillators, or other metal fragments in or near the head. There is a remote risk of external 
injury to the body when metal outside of the magnet is brought close to the scanner. However, scanners are located in secure rooms to avoid inadvertent introduction of metals into the magnetic field. Other than injuries from unsecured metal materials, there are no known longstanding detrimental health effects associated with exposure to high magnetic fields, magnetic gradients, or radiofrequency energy used in MRI. Because the procedure requires participants to lie still inside a narrow tube, participants may experience claustrophobia or mild body position discomfort.  
 
Lumbar Puncture. The risk for serious AE related to LP (e.g., post-LP headache, infection, 
nerve root damage) is very low.80 LP may be associated with pain during the procedure. This is 
ADC-041-EX   Page 22 of 78 
 
 Version 7.0: 18NOV2021 
   
 usually temporary and confined to the lower back.  Headache may occur in about 5% of elderly 
adults who receive an LP using the ADCS LP protocol .  Less commonly, in about 1- 4% of 
subjects, a persistent low -pressure headache may develop, probably due to leakage of CSF.  
On rare occasions, a blood patch (injection of some of the subject’s blood to patch the CSF 
leak) may be needed.  Potential but rare risks of LP  include infection, damage to nerves in the 
back, bleeding into the CSF space, and death. Risk for these events is less than 1%. 
 
General. Blood collection may be associated with transient discomfort and bruising, and a small 
risk of infection. Cognitive testing may produce frustration in some subjects. Questionnaires 
about mood may uncover or potentiate feelings of dysthymia and helplessness.   
 
5.0 SAMPLE SIZE AND STAT ISTICAL PLAN  
 
This study is a multisite, randomized, single-blind trial comparing the effects of supervised 
moderate/high intensity aerobic exercise (70-80% HRR) versus stretching/balance/range of 
motion ( ≤35% HRR)  in adults with MCI (N =300). 
 
 Randomization 
 In this single -blind study desi gn, eligible participants per site will be randomized using a simple 
1:1 schedule to either the AX or SBR group, and stratified by s ite, ApoE4 carrier status (yes or 
no), and gender . After 12 months of supervised exer cise, all participants will transitio n to 
independent exercise (without supervision) and will be instructed to continue their assigned physical activity  regimen for an additional [ADDRESS_544586] the efficacy of a translational model. 
 
 Power and Sample Size D etermination 
 Power calculations f or EXERT were based on two-sample t-tests.
81 Sample sizes were 
estimated using 12-month ADAS -Cog change scores from the ADCS MCI trial, targeting power  
=80%, 2-sided alpha =5%, and SD  =4.1. Calculations ranged over effect sizes in ADAS -Cog 
from 1.0– 2.0, and dropout rates from between 10-25%, which are similar to other reports, 
including multi -center trials of physical activity interventions in older cohorts.11,16,17,31,82,83 The trial 
is powered to conservatively accommodate 20% attrition. Based on these considerations, and 
an effect size = 1.5, [ADDRESS_544587] on biomarkers, the difference in hippocampal atrophy between ADNI MCI participants versus healthy controls (HCs) without the ApoE4 allele was 
used. With a total sample size of 300, assuming 20% attrition and SD = 1.54 (based on ADNI 
data), power to detect a difference in percent change from Baseline to Month 12 in hippocampal 
ADC-041-EX   Page 23 of 78 
 
 Version 7.0: 18NOV2021 
   
 volume between intervention groups as small as 0.56%, is 80% (5% alpha). As a reference, the 
difference in percent change from Baseline to Month 12 in hippocampal volume between ADNI 
MCI and normal controls ApoE4 non-carriers (presumed to be free of disease) is estimated to be 1.02%. Thus, the study is powered to detect an improvement equivalent to 0.559/1.02 
=54.8% of this ApoE4 related effect. With regard to entorhinal cortical thinning, assuming SD 
=1.68 (ADNI data), power to detect a difference in percent change from Baseline to Month 12 as 
small as 0.61% between intervention groups  is estimated at 80%. Again as a reference, the 
difference in percent change from Baseline to Month 12 between ADNI MCI and normal controls 
ApoE4 non-carriers is estimated to be 1.49%. Thus the study is powered to detect an 
improvement equivalent to 0.61/1.49 =40.9% of this ApoE4 related effect.  The preceding calculation assumes a maximal intervention effect would result in normalization of atrophy to the rate seen in healthy controls. However, Erickson et al .
31 report hippocampal 
expansion with exercise in non-demented older adults. Here, 120 subjects completed a 
12-month program of aerobic exercise (mean age+/-SD:  67.6yrs+/-5.81yrs) or stretching 
(65.5yrs+/-5.44yrs), and were tested at baseline, and at months 6 and 12. The aerobic group had significant increases in left and right hippocampal volumes (2.12% and 1.97% change from 
baseline, respectively) after 12 months. For the stretching group, left and right hippocampal 
volumes decreased (-1.40% and -1.43% change, respectively) after 12 months (all p’s<0.001). 
Assuming an effect as large as that observed in Erickson et al. (~2%) and ADNI estimated standard deviation of change (SD  =1.7), 20% attrition, and 2 -sided alpha  =5%, 300 randomized 
participants  should provide greater than 99% power. Despi[INVESTIGATOR_430507]., EXERT is conservatively powered to detect a relatively modest normalization of 
hippocampal atrophy. 
 
 Selection of Participants to be Used in A nalysis 
 
The modified intent to treat (mITT) population will be used for primary analysis. The mITT 
population will include all eligible individuals who, (1) began the exercise intervention and (2) 
completed at least one post-baseline assessment for the primary analysis . Exploratory analyses 
will include a per-protocol population of all eligible participants  who, (1) completed the 12-month 
assessments for the primary analysis, (2) participated in at least 60% of the prescribed exercise sessions, and (3) met exercise goals in at least 60 % of the supervised sessions , and an intent-
to-treat (ITT) population of all eligible individuals who are randomized. 
 
 Efficacy A nalysis  
 
5.4.[ADDRESS_544588] 12 months will be analyzed using a mixed effects model for repeated measures 
(MMRM) to assess differences in scores between intervention groups. The MMRM model will 
include terms for time, intervention, and baseline ADAS -Cog-Exec , intervention-by -time 
ADC-041-EX   Page 24 of 78 
 
 Version 7.0: 18NOV2021 
   
 interaction, baseline ADAS-Cog -Exec  by [CONTACT_6491], plus covariates that include site, 
ApoE 4 carrier status , sex , and additional covariates  meeting the criteria below.  
 
Time will be treated as categorical. An analysis of covariance model imputing missing data with 
multiple imputation will be used as a sensitivity analysis. As a second sensitivity analysis, a similar MMRM model will be fit with time modeled as a continuous factor. If the longitudinal patterns over time are markedly non-linear, such as might occur due to learning effects, a quadratic term for time will be included in the model. In this case the intervention-by -time linear 
term assesses whether there is a relative difference between intervention groups that grows 
linearly with time. Potential  confounders (baseline Walk Test time, age, education, 3MSE 
baseline score, and use of cholinesterase inhibitors) will be included in efficacy analyses as covariates if the following two conditions are satisfied: (1) imbalance at baseline (p<0.1) and, (2) 
association between the covariate and the response (p<0.15). Safety data will be analyzed 
using exact contingency table methods by [CONTACT_430566] . 
 Differences in the primary outcome of change in ADAS -Cog-Exec between intervention groups 
will be tested at the two-sided 5% significance level. No adjustment to the type 1 error level will be made for secondary analyses.  
 
5.4.2 Analyses of Secondary Outcomes 
 
Aims 2–4 : Similar analyses to that described for the primary analysis  will be performed on the 
Clinical Dementia Rating Scale – Sum of Boxes  (CDR-SB), ADAS- Cog13 total score, Executive 
Function and Epi[INVESTIGATOR_49564] M emory Composites , tests of daily living skills (ADCS –Activities Of Daily 
Living– MCI [ADCS -ADL-MCI] , Behavior Rating Inventory Of Executive Function– Adult Version 
[BRIEF-A]),
 mood and health-related quality of life ( Neuropsychiatric Inventory  [NPI], 36-Item 
Short-Form Health Survey  [SF-36]), EuroQol 5-Item Health Questionnaire [EQ5D]), and 
subjective memory concerns (Cognitive Change Index) . 
 
Aim 5: Change in brain volume and inter -regional correlations in brain functional activity will be 
compared between treatment groups. The anal ysis will be completed separately for each 
volumetric and functional MRI parameter. 
 
Aim 6: CSF biomarkers of brain health and disease will be examined using a similar analytic 
strategy to that described for the analysis of the primary outcome using MMRM and other 
sensitivity models to test for intervention effects. Covariate adjustment, sensitivity analyses, and 
multiple imputation analyses will be carried out as specified under Aim 1.  
 
Aim 7: To examine whether sociodemographic factors, genotype, actigraphy outcomes, or 
baseline cognitive and biomarker profiles predict treatment response, MMRM and sensitivity 
models as described above will be performed using subgroup analyses. Model fitting  and 
covariate adjustment will be carried out as specified under A im 1.  
 
  
ADC-041-EX   Page 25 of 78 
 
 Version 7.0: 18NOV2021 
   
 Aim 8: To examine the enduring cognitive and behavioral effects  of the intervention following 
the 6-month unsupervised exercise extension, MMRM and sensitivity models as described 
above will be performed. Model fitting and covariate adjustment wil l be carried out as specified 
under Aim 1.  
 
Aim 9: To examine the impacts of the intervention on the study partner , MMRM and sensitivity 
models as described above will be performed on data obtained using the Study Partner Self-
Assessment Questionnaire.  
 
 Safety A nalysis  
 Safety will be assessed by [CONTACT_430567]. 
Adverse events will be coded according to established Medical Dictionary for Regulatory Activities (MedDRA) terms and summarized by [CONTACT_224190]. Treatment-emergent adverse events (T EAE) will be defined as events that first occurred 
or worsened on or after randomization. 
 An overview  of AEs, including the number and percentage of participants  who died, suffered 
SAEs, discontinued due to AEs, and who suffered TEAEs, will be provided. A comparison 
between intervention arms  will be performed. Summaries  of AEs by [CONTACT_430568] : (1)   pre-e xisting conditions , (2) TEAEs, and (3) SAEs. D iscontinuations due 
to AEs will also be listed.  
 
 T ermination of the Trial   
 No criteria for trial termination are specified. If safety or efficacy issues are identified during trial conduct, the Data and Safety Monitoring Board (DSMB)  may decide to stop the study.
 
 
6.[ADDRESS_544589] 8 exercise sessions completed (weeks 1 and 2), and for [ADDRESS_544590] efficiency, T rainer s will provide 
supervision to small groups of participants (2-4 individuals) randomized to the same intervention 
whenever possible. Compliance will be evaluated using multiple mechanisms including HR 
monitoring, participant ratings of perceived exertion, entries in participants’ Physical  Activity 
Logs, Trainer assessment of effort, and weekly data review by [CONTACT_430569]-Project Manager (Y -
ADC-041-EX   Page 26 of 78 
 
 Version 7.0: 18NOV2021 
   
 PM) and the Intervention Oversight Team (includes the PDs, Wake Forest team of exercise trial 
specialists, and Y-[LOCATION_003] ). These mechanisms will provide multiple and regular opportunities to 
discuss participant progress, identify and resolve barriers, and encourage high levels of 
adherence to study protocols. The Intervention Oversight Team has the necessary expertise to 
successfully accomplish this objective in EXERT.  
 
 Collaboration with the YMCA  
 EXERT has partnered with the national office of the YMCA (referred to as ‘ Y-[LOCATION_003] ’) to provide 
exercise facilities and trained personnel to supervise participants as they complete their assigned intervention protocols. The YMCA Trainers maintain certifications to keep current w ith 
latest knowledge about fitness and its practice , and have experience supervising older adult 
exercise. This collaboration with the Y -[LOCATION_003] will move the field forward in  bridging the rift 
between academic research and health care delivery, thus providing additional important 
translational value to the study.   Study -certification of Trainers  will involve completion of training regarding the study protocol, 
proper implementation of the interventions, data capture of adherence outcomes, and AE recording and reporting.    
 Intervention adherence data will be recorded by [INVESTIGATOR_339429] s on Case Report Forms (CRFs) during 
supervised exercise sessions and will include type of exercise completed, HR during exercise, 
ratings of perceived exertion, and exercise duration a nd intensity . During supervised sessions, 
Trainer s will also review participant s’ Physical  Activity Logs to ensure they  are properly 
completed and study goals are met , and complete an AE Checklist that will be faxed to the clinic 
for review  and follow -up as per study protocol (see Sections 14 and 15).   The Trainers and Y -
PMs will provide regular updates as requested by [CONTACT_941] c linic, the Intervention Oversight Team, 
and the ADCS.  All Y -PMs will attend a telephone conference twice per month, attended by 
[CONTACT_430570], the Intervention Oversight Team, and the ADCS to ensure efficient 
coordination and implementation of the intervention protocols. Trainers will also attend at least 
one telephone conference call per month with members of the Intervention Oversight Team.  
6.2.[ADDRESS_544591] of the following:  
 
Y-[LOCATION_003] . The Senior Manager of Program Development for Y -[LOCATION_003], and the Y-[LOCATION_003] Study 
Manager will serve as the primary interface between the national office of the YMCA, the PDs, 
the Wake Forest team, the ADCS, the participating YMCA Associations, and the Y-PMs .  
  
YMCA Project Manager (Y-PM) . The site Y -PM, a senior level staff member will oversee T rainer  
supervision of EXERT participants, review and upload all adherence data to the central data 
repository, respond to adherence data queries as needed, and maintain a close bidir ectional 
relationship with the clinic to facilitate efficient monitoring of participant progress and 
ADC-041-EX   Page 27 of 78 
 
 Version 7.0: 18NOV2021 
   
 management of study -related issues. The site Y- PM will report all AEs to the clinic , maintain 
regular communication with the Clinic YMCA Liaison regarding participant progress, and 
participate in bi -weekly conference calls with other site Y -PMs  and Clinic YMCA Liaisons , the 
Intervention Oversight Team, and the ADCS  to review study progress and address challenges 
as they arise.  
YMCA Trainers. Trainers at each site will supervise participants , providing encouragement and 
exercise-related expertise to help participants achieve the targeted intervention goals and to maintain high levels of adherence throughout the trial. During supervised sessions, T rainer s will 
record adherence data on CRFs, review participant Physical  Activity Logs to identify and 
address challenges and assess adherence, complete the AE Checklist, mai ntain close 
communication with the Y-PM and the Clinic YMCA Liaison regarding participant progress and, as schedule permits, participate in twice per month conference calls to review study progress with other T rainer s, Y-PMs, Clinic YMCA Liaisons, the Intervention Oversight Team, and the 
ADCS . 
 
6.2.[ADDRESS_544592] (IRB), the Intervention Oversight Team, and the 
ADCS.  
 Once randomized, the site Y-PM will be notified by [CONTACT_430571]’s contact 
[CONTACT_430572]. 
The sharing of contact [CONTACT_430573]. The 
Y-PM will review all adherence CRFs completed by [CONTACT_224658] s during supervised exercise 
sessions, and will enter and upload all compliance data to the ADCS Electronic Data Capture 
(EDC) and respond to any associated data queries.     
 
6.2.[ADDRESS_544593] week, and will include questions 
to identify potential SAEs (death, life -threatening, hospi[INVESTIGATOR_059], disability or permanent 
damage). The AE Checklist  will also query TEAEs, which most commonly include muscle or 
joint aches including flare-ups of pre -existing musculoskeletal conditions (e.g., arthritis, foot 
bone spurs or neuromas). The AE Checklist will be faxed to the c linic to permit review by [CONTACT_430574] C linician  within [ADDRESS_544594] judgment of 
YMCA staff, the EMS may be engaged to stabilize and transport an individual to a nearby 
[CONTACT_360936]-041-EX   Page 28 of 78 
 
 Version 7.0: 18NOV2021 
   
 hospi[INVESTIGATOR_297363]. Other standard YMCA protocols may be used in the event of an onsite 
injury or medical event.  
 
 Implementation of the Interventions 
 Both intervention groups will complete their assigned exercise at participating YMCA  branches 
near the selected clinics . Intensity and duration of exercise in both groups will be gradually 
increased over the first 6 w eeks  in the study, and then maintained at the intervention-specific 
targeted level (described in Sections 6.3.1 and 6.3.2) for the remainder of the 18-month 
intervention.  
 All participants will be provided with a digital HR monitor that includes a chest strap and a wrist-
worn monitoring device and watch, and taught to use this device to monitor and record HR while 
exercising. Partici pants taking medications with HR-lowering effects will be provided with HR 
monitors, but will be taught to rely more heavily on other measures of effort intensity such as breathing rate, and ability to talk while exercising. During supervised sessions, effort will also be assessed by [CONTACT_224658] s. Participants in both intervention groups will be trained to properly use 
the Rating of Perceived Exertion (RPE) modified Borg scale (ratings range from 1=very mild, to 
10=very, very hard) in the first [ADDRESS_544595] HR and RPE 
every 5-10 minutes, as well as  other relevant exercise parameters (e.g., total duration, type of 
exercise completed, treadmill speed and grade). The T rainer will also record any additional 
observations that might assist the Intervention Oversight Team in their weekly review of 
participant progress. These data will be uploaded to the EDC by [CONTACT_941] Y -PM within [ADDRESS_544596] the following in their Physical  Activity Log: date and time, type of exercise, exercise duration, 
average HR, maximum RPE achieved, and other intervention-specific details (e.g., body regions 
stretched, grade/resistance and speed of equipment used). During each supervised session, the 
Trainer  will review these entries, discuss and problem -solve issues that are uncovered during 
this review, and confirm the exercise schedule for the next few days. At the Baseline, Month 6, 
and Month [ADDRESS_544597] completed Logs  and store them 
in a locked cabinet until retrieved by [CONTACT_430575], which will occur monthly . In the 
final 6 months of the study (unsupervised), participants will return the last set of 6 completed 
Physical Activity Logs  to the clinic at the Month 18 visit. 
 Progression through the 18-month intervention will involve transition from one ‘ phase’ to 
another. This transition will provide an objective measure of progress for participants, and a 
structure that will facilitate Trainer, Y -PM, and Intervention Oversight Team efforts to anticipate 
ADC-041-EX   Page 29 of 78 
 
 Version 7.0: 18NOV2021 
   
 and address participant issues that may characteristically change as they advance through the 
study  (e.g., development of mastery, boredom with routines) . The phases will also differ with 
regard to study expectations of participants and emphasis in training, which will shift from the 
basics of the prescribed exercise routines in the early part of the study to strategies to support 
and maintain independent exercise later in the program. The phases are defined by [CONTACT_430576] , where ‘month’ always refers to exactly 4 weeks.   
 
• In Phase 1 (m onths 0-3), participants will receive instruction about the program and any 
equipment to be used, about proper form and technique, attire, exercise facility  etiquette 
and symptoms of fatigue and injury, and exercise expectations will be gradually 
increased with the goal of reaching intervention-specific  activity  goals by [CONTACT_199487] 
6 (i.e., 70-80% HRR for the AX  group; ≤35% HRR for the SBR  group). T raining will also 
focus on participants’ self-efficacy to begin to develop a strong foundation that will support adherence to the interventions over long periods of time. Participants will be asked to limit travel as much as possible, and will not be permitted to engage in alternate exercise activities (classes, outside walking). For all participants, the first 8 sessions of exercise will be supervised by a study -certified YMCA Trainer.   
 
• In Phase 2 (m onths 4-6) , the goal will  be for participants to begin to develop mastery of 
the intervention-specific  activities. In Phase 2, participants will be allowed to engage in 
2 alternate activities per month (e.g., aerobic or easy yoga classes). Alternate activities 
must receive prior approval by [CONTACT_430577] Y-PM to ensure that the activity is 
consistent with participant-specific intervention goals. Continued participation in [ADDRESS_544598] to approval by [CONTACT_430578]’s adherence record. The opportunity for participants to engage in alternate activities serves as a reward and thus an adherence-promoting strategy.   
 
• In Phase 3 (m onths 7-9 ), participants’ target HR will be re-calculated using the most 
recent resting HR measurement obtained during the Month 6 clinic assessment. This 
reassessment will ensure that the intervention-specific HR training goals  are 
appropriately adjusted for  current fitness levels (using surrogate measure of resting HR). 
In Phase 3, participants will continue their prescribed activities using the same supervision schedule, and will have the opportunity to engage in 1 pre- approved 
alternate activity per week  (e.g., aerobic or easy yoga class ). As in  Phase 2, continued 
participation in alternate activities will be subject to approval by [CONTACT_430579]. 
 
• In Phase 4 (m onths 10-12), participants will adhere to the same exercise regimen 
(4 times per week) and supervision schedule (twice per week), and will continue to have 
the opportunity to participate in [ADDRESS_544599] to 
approval by [CONTACT_430580]. The supervised sessions will include training and discussions to prepare participants for independent exercise.  
 
ADC-041-EX   Page 30 of 78 
 
 Version 7.0: 18NOV2021 
   
 • In Phase 5 (months 13-18), participants will transition from supervised to unsupervised 
exercise following the Month [ADDRESS_544600] electronic scan records  
and partic ipant-recorded entries in Physical Activity Logs .  
 
6.3.1 Aerobic Training Intervention 
 
The aerobic exercise (AX) will consist of treadmill walking supplemented with use of the elliptical 
trainer  or stationary cycle  at moderate/high to high level s of cardiorespi[INVESTIGATOR_430508], defined 
as 70-80% of HRR (HRR =220-age-resting HR ) for 30 min, 4 days per week. Each session will 
include an additional 10 minutes of warm -up and an additional 5 min for cool -down. In study  
Phases 2-5, participants will be permitted to attend pre-approved aerobic exercise classes at the YMCA to encourage continued participation over the duration of the 18-month trial. High 
levels of retention (>80%) and adherence (>90%) have been achieved in previous exercise 
trials in healthy and memory -impaired older adults.
16,20,82,84,85 
 The following algorithm  – previously used in studies of older, sedentary adults
16,20,79 – will be 
used to establish AX HR targets and exercise durations during the initial ramp -up period and for 
the remainder of the 18-month progr am: 
 
Exercise Goals Week Warm -Up,  
Cool -Down Time  RPE Effort, Time in 
Training HR Zone  
Target HR = 50 -60% HRR ; 
Total Duration = 15-25 minutes  1 3 min , 2 min 1 – 2 50%, 10  min 
2 5 min , 5 min  3 – 4 60%, 15  min 
Target HR = 65 -70% HRR; 
Total Duration = 30 -45 minutes 
 3 5 min , 5 min  4 – 5 65%, 20  min 
4 5 min, 5 min  5 – 6 65%, 25  min 
5 5 min, 5 min  5 – 7  65%, 30  min 
6 10 min, 5 min  6 – 8  70%, 30  min 
Target HR = 70 -80% HRR;  
Total Duration = 45 minutes  7+ 10 min, 5 min  6 – 8 75%, [ADDRESS_544601] difficulty meeting the exercise intensity and duration goals due to 
physical limitations (e.g., musculoskeletal issues, obesity), or lowering of training HR targets for 
a period of time to permit participants to adjust to the program or recover from injury or unanticipated prolonged inactivity. Adjustments to the AX algorithm will be regularly reviewed by 
[CONTACT_430581].   
  
ADC-041-EX   Page 31 of 78 
 
 Version 7.0: 18NOV2021 
   
 6.3.2 Stretching, Balance, and Range of Motion I ntervention 
 
The stretching, balance, and range of motion (SBR) intervention will include a rotating and 
varied routine of stretching exercises for large and small muscle groups, and activities to improve balance and range of motion. SBR activities will be tailored so that participants are able 
to maintain HR at or below 35% HRR during each session, which will be completed 4 days per 
week  for 45 min per session.  
 
The SBR algorithm  described below will be used to establish HR targets and exercise duration 
during the ramp -up period and for the remainder of the 18-month program . The algorithm serves 
as a guideline and can be adjusted by [CONTACT_430582]. For example, 
adjustments to the SBR regimen may be required if achieved HR consistently exceeds the 
maximum allowable target. If HR continues to rise even under very low exercise demands (e.g., 
cardiac response to gentle stretches may be greater for obese or severely deconditioned 
adults), new maximum HR targets may be set, subject to revision as participants become 
accustomed to physical activity. Adjustments to the SBR algorithm will be regularly reviewed by 
[CONTACT_430581].  
 
Exercise Goals Week Warm -Up, 
Cool -Down Time  RPE Total Exerci se 
Duration  
Target HR ≤ 35% HRR  1 3 min, 2 min  1 – 2 15 min  
2 5 min, 5 min  1 – 3 20 min  
3 5 min, 5 min  1 – 3 25 min  
4 5 min, 5 min  1 – 3 30 min  
5 5 min, 5 min  1 – 3 35 min  
6 5 min, 5 min  1 – 3 40 min  
7+ 5 min, 5 min  1 – [ADDRESS_544602] 80% of the prescribed exercise sessions. Participants who 
miss a supervised exercise session will be contact[CONTACT_63819] T rainer  to confirm that the 
participant will attend the next scheduled supervised session. Participants who miss [ADDRESS_544603] the Y -PM 
and Clinic YMCA Liaison to discuss strategies to increase adherence. Participants who do not 
ADC-041-EX   Page 32 of 78 
 
 Version 7.0: 18NOV2021 
   
 attend at least 10 supervised or unsupervised sessions per month will be counseled to improve 
attendance, and motivational strategies to increase adherence and limit obstacles to study 
participation will be implemented if necessary (e.g., goal setting, reinforcers identified and 
scheduled, etc.). In the first [ADDRESS_544604] 
of absence who miss 48 exercise sessions within a 3-month period will be dropped from the intervention due to non-compliance.   If a participant misses a supervised exercise session for reasons that are unplanned (excludes missed visit for holiday closure, weather, and other anticipated reasons), a Missed Visit CRF will 
be completed by [CONTACT_430583] Y -PM to permit tracking of these 
events .  
 For planned travel, total time away must be no more than a total of [ADDRESS_544605] be willing to continue the assigned exercise unsupervised if travelling out of 
the area for more than 1 week. For all planned absences, the T rainer  will meet with the 
participant in advance to develop an acceptable program  for continued exercise.  
 Although high levels of adherence will be stressed at all times, adherence will be particularly 
important in the 4 weeks preceding the Month 6 and Month 12 assessment clinic visits. At the 
Intervention Oversight Team’s discretion and in consultation with the site Principal Investigator  
(PI), the acceptable window for completion of these visits may be expanded by [CONTACT_8622] [ADDRESS_544606]-practice exercise guidelines including warm-up and cool -down activities, positioning and shifting of body weight, 
proper form, safety around exercise equipment, exercise quantity (intensity, duration frequency) and attire to minimize risk of discomfort and injury. These discussions between the T rainer  and 
participant will be initiated on Day [ADDRESS_544607] between assessment visits.  
 
ADC-041-EX   Page 33 of 78 
 
 Version 7.0: 18NOV2021 
   
 During supervised sessions, the T rainer will monitor HR, breathing rate, and other signs of 
physical effort. Sessions will be terminated and clinic staff immediately notified if any  of the 
following symptoms become apparent:  
 
• Resting HR is <40 beats per minute ( bpm) or >120 bpm  
• Unusual or severe shortness of breath 
• Chest pain, including chest discomfort or pressure, left arm pain, report of indigestion or 
stomach discomfort 
• Palpi[INVESTIGATOR_814]  
• Fainting, light headedness, dizziness   
 
A supervised session may also be terminated if participants complain of musculoskeletal pain 
that contraindicates continued safe exercise. 
  
 Temporary Intervention Discontinuation 
 There may be situations that arise that will warrant temporary discontinuation of the intervention 
for a participant. When these events occur, the Intervention Oversight Team, Y -PM, Trainer, 
and Clinic YMCA Liaison will develop a plan during twice per month meetings to keep the 
participant engaged in the study while ‘on hold’  and to reengage the participant once the 
situation has resolved. The decision to remove a participant from the study in the event of a 
prolonged Temporary Intervention Discontinuation will be made by [CONTACT_430584] , in consultation with the site PI [INVESTIGATOR_430509], on a case-by -case basis.  
 A participant will be classified as being medically ‘on hold’  if 4 or more consecutive exercise 
sessions are missed due to self-reported hospi[INVESTIGATOR_059], injury or other health issue (vacations 
excluded), or is withdrawn from physical activity as per  primary care provider ( PCP) orders. If a 
participant is on hold, the Trainer, Y-PM, or Clinic YMCA Liaison wi ll contact [CONTACT_430585].  
 Restart following soft tissue injuries without surgery can occur when the participant self-reports 
an ability to continue the intervention. Restart following other medical complications will require 
prior approval by [CONTACT_430586]. The site PI [INVESTIGATOR_430510]’s  PCP 
approval for re -start as well. C ommunicati on with participants  on medical leave regarding their 
status in the study should always emphasize that they are ‘on hold’ rather than ‘temporarily 
suspended’ or ‘on leave’  to encourage continued psychological /emotional  commitment to the 
study, which will likely expedite restart when appropriate to do so.  
 
 Reasons for Temporary Discontinuation 
 Reason(s) for temporary intervention discontinuation will be captured in the  appropriate CRF 
and coded as follows:  
 
• Adverse experience: The participant has experienced an AE  that, in the opi[INVESTIGATOR_430511]-041-EX   Page 34 of 78 
 
 Version 7.0: 18NOV2021 
   
 investigator , requires temporary intervention discontinuation; this may include abnormal 
laboratory values.  
• Safety r isk: Any participant who is deemed a safety risk by [CONTACT_430587] a 
temporary condition.  
• Study temporarily suspended by [CONTACT_360972].  
• Investigator judgment that it is in the participant’s or study’s best interest to temporarily 
discontinue the intervention until ongoing personal or medical issues no longer interfere 
with participation, including unanticipated prolonged travel or medical issues (e.g., surgery, accidents, development of new medical conditions), and family matters. 
• Intervention Oversight Team judgment that it is in the participant’s or study’s best 
interest to temporarily discontinue the intervention until ongoing personal or medical issues no longer interfere with participation, including unanticipated prolonged travel or medical issues (e.g., surgery, accidents, development of new medical conditions), and family matters. 
 
 Timing of Temporary Discontinuation Relative to Assessment of Primary and Secondary Outcomes 
 
If a temporary intervention disconti nuation occurs near the time of the scheduled Month [ADDRESS_544608] 3 weeks prior to the assessment. If longer delays are required to 
meet this goal, the assessment visit will be completed according to the original schedule. The 
decision to postpone an assessment visit will be made by [CONTACT_430588] , in 
consultation with the site PI [INVESTIGATOR_430509], on a case-by -case basis.  
 
 Blinding   
 
The S tudy Clinician and the Clinic YMCA Liaison will be unblinded to intervention group 
assignment; all other clinic staff will remain blinded. The Study C linician will be responsible for 
reviewing and following up on all AEs. The Clinic YMCA Liaison serves as the primary interface 
between the participating YMCA and the clinic, and thus  will be exposed to intervention-specific 
details for participants. The description of TEAEs may relate to physical activities completed as part of the assigned intervention. Disclosure of randomization assignment will occur in the clinic by [CONTACT_430589] C linician.  
 
It will be critically  important that the clinic staff member(s) who administer the cognitive and 
functional assessment instruments to participants (referred to as ‘Raters’) remain blinded. 
Unblinded staff will not discuss any details about a participant’s intervention or progress with the 
Rater, and the Rater will not have access to any intervention-related data, including AEs, 
supervised exercise adherence data, or participant Physical Activity Logs. Participants will be 
instructed by [CONTACT_430590] (other than the Study C linician ). Signs will be clearly posted in all testing rooms to remind participants to not 
ADC-041-EX   Page 35 of 78 
 
 Version 7.0: 18NOV2021 
   
 share information about their  assigned exercise program, and Raters will also remind 
participants to keep this information to themselves at frequent intervals. These procedures to 
ensure that the Rater remains blinded to intervention assignment have been used with success in other randomized clinical trials of aerobic exercise in non- demented older adults.
16,[ADDRESS_544609] document 
the following information on a Blind Break Notification Form for the participant: date, personnel 
exposed, and why/how blind was broken. An alternate plan for assessment of primary outcomes 
at future clinic visits ma y be requested by [CONTACT_430591].    
 
 Concomitant AD Medications  
 
Stable use of memantine  or cholinesterase inhibitors  at study entry will be permitted (3 or more 
months at a consistent dose with no plans to modify). Participants who start AD medications 
after enrollment will be permitted to continue in the study.  
7.[ADDRESS_544610] scores and clinical ratings consistent with a mnestic 
MCI will be enrolled into EXERT. To determine eligibility , all participants will undergo cognitive 
assessment, physical and neurological examination, electrocardiogram ( ECG ), clinical/safety  
laboratory assessment, and interview s of the participant and study partner . 
 
 Inclusion Crit eria  
 1. Age between 65 and 89 years old, inclusive  
2. MMSE: ≥ 24 for participants with 13 or more years of education; ≥[ADDRESS_544611] 6 years of formal education or work history sufficient to exclude mental 
retardation  
ADC-041-EX   Page 36 of 78 
 
 Version 7.0: 18NOV2021 
   
 8. Has an informant who knows the participant well, has regular  contact, and is available to 
accompany the participant to clinic visits  or complete study partner assessments remotely.   
9. Sedentary or underactive, determined by [CONTACT_430592]-administered EXERT 
Telephone Assessment  of Physical Activity (TAPA) survey  
10. Willing to be randomized to either intervention group and to complete the assigned activities 
as specified for [ADDRESS_544612] be no more than 2 months over the course of the 
study, and no more than 1 month at any one time; participants must be willing to continue 
the assigned exercise program  if travelling out of the area for more than 1 week  
15. In overall good general health with no disease or planned surgery that could interfere with 
study participation  
16. Modified Hachinski ≤4  
17. Stable use of cholinesterase inhibitors, memantine, vitamin E , estrogens, aspi[INVESTIGATOR_248] (81-300 mg 
daily), beta-blockers, or cholesterol -lowering agents for 12 weeks prior to screening 
(important for biomarker analyses)  
18. Stable use of antidepressants lacking significant anticholinergic side effects for [ADDRESS_544613] 12  months; GDS scores are to be used to inform clinical 
decisions but there is no specified cut -off score for inclusion  
19. When applicable, willing to complete 4-week washout of psychoactive medications, 
including disallowed antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, 
and willing to avoid these medications for the duration of the trial 
20. Able to complete all baseline assessments  
 
 Exclusion Criteria  
 1. Any significant neurologic disease, other than MCI, including any form of dementia, Parkinson’s disease, Huntington’s disease, normal pressure hydrocephalus, brain tu mor, 
progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or 
history of significant head trauma with persistent neurologic sequelae or known structural 
brain abnormalities  
2. Sensory or musculoskeletal impairment sufficient to preclude successful and safe 
completion of the intervention or assessment protocols; must be able to walk safely and unassisted on a treadmill  
3. Contraindications for MRI studies, including claustrophobia, metal (ferromagnetic) implants, or cardiac pacem aker  
4. Brain MRI at screening shows evidence of infection, infarction, or other clinically significant focal lesions, including multiple lacunes in prefrontal or critical memory regions; i nconclusive 
findings may be subject to review by [CONTACT_430593] e 
ADC-041-EX   Page 37 of 78 
 
 Version 7.0: 18NOV2021 
   
 5. History of major depression or bipolar disorder (DSM V criteria), psychotic features, agitation 
or behavioral problems within the last [ADDRESS_544614] 2 years, as per DSM V 
criteria 
8. Currently consumes more than 3 alcoholic drinks per day  
9. Clinically significant or unstable medical condition, including uncontrolled hypertension or 
significant cardiac, pulmonary, hematologic, renal, hepatic, gastrointestinal, endocrine, metabolic or other systemic disease in the opi[INVESTIGATOR_430512], influence the results or compromise the participant’s ability to participate in the study (treated atrial fibrillation for more than 1 year or occasional premature ventricular contractions on ECG are not exclusions)  
10. History in the last [ADDRESS_544615] 3 months  of transient ischemic attack or small vessel stroke (if more than 
3 months, small vessel stroke with no residual effects are permitted)  
12. Expected joint replacement surgery within the next [ADDRESS_544616] 5 years of a primary or recurrent malignant disease with the exception of non-melanoma skin cancers, resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with normal prostate-specific antigen posttreatment 
14. Hemoglobin A1c >7.0  
15. Clinically significant abnormalities in screening laboratory blood tests: low B12 is exclusionary, unles s follow -up labs (homocysteine [HCY] and methylmalonic acid [MMA]) 
indicate that it is not physiologically significant  
16. Current or past use of insulin to treat type 2 diabetes (other diabetes medications are 
acceptable if hemoglobin A1c 
≤7) 
17. Current use (within 60 days of screening) of psychoactive medications including tricyclic 
antidepressants, antipsychotics, mood-stabilizing psychotropic agents (e.g. lithium salts), 
psychostimulants, opi[INVESTIGATOR_199707], antiparkinsonian medications, anticonvulsant medications (except gabapentin and pregabalin for non-seizure indications), systemic 
corticosteroids, or medications with significant central anticholinergic activity . Limited use of 
antipsychotics (quetiapi[INVESTIGATOR_050] ≤ 50mg/day or risperidone ≤ 0.5mg/day), and non-chronic use of 
opi[INVESTIGATOR_430513]; such medications must be avoided for 
8 hours before clinic assessments  
18. Chronic use of anxiolytics or sedative hypnotics except as follows: use of benzodiazepi[INVESTIGATOR_430514] -needed basis for insomnia or daily dosing of anxiolytics is permitted; 
medications must be avoided for [ADDRESS_544617] amyloid are prohibited 12 months prior to screening and for 
the duration of the trial; treatment with other investigational agents are prohibited 3 months 
prior to screening and for the duration of the trial  
21. For LP, current use of anticoagulants such as Coumadin, Plavix , or high dose Vitamin E   
ADC-041-EX   Page 38 of 78 
 
 Version 7.0: 18NOV2021 
   
 22. For LP, current blood clotting or bleeding disorder, or significantly abnormal prothrombin 
time (PT) or partial thromboplastin time (PTT) at screening  
23. For LP, presence of physical distortions due to spi[INVESTIGATOR_61691], severe degenerative joint disease or deformity, or obesity that could interfere with CSF collection (as per i nvestigator 
judgment)  
24. Participants whom the PI [INVESTIGATOR_430515] 
 A recruitment plan will be developed in coordination with the ADCS and it s study partners. The 
plan will include national media releases and EXERT-specific study materials that can be used by [CONTACT_430594]. Multiple 
strategies will be used to promote high rates of retention, including twice weekly meetings with 
the Trainer, opportunities to participate in group exercise activities, and by  [CONTACT_430595] (e.g., quilts, T-shirts, exercise 
accomplishment reports).  
 
 I nclusion of Women and M inorities 
 
No subject will be excluded for reasons of sex, race, or ethnic group. There are currently no studies that definitively support or negate differences in response to aerobic exercise within these subgroups. Consistent with the aims of the ADCS Minority Recruitment Core, EXERT  will 
target a minimum of 20%  racial/ethnic minority representation in the sample of 300 older adults.  
 8.0 STUDY TIMELINE   
 
Study participation will include up to 6 weeks between Screening II (Visit 1) and Baseline (Visit 
2), 12 months of supervised exercise at a local YMCA facility, and 6 months of unsupervised 
exercise at the YMCA.  
 9.0 DESCRIPTION OF STUDY  VISITS  
 The schedule of events  is provided in Appendix 1.  
 
 Screening I (Visit 0)  
 Prior to the in-person screening evaluation, the investigator will identify potential participants through routine clinical contact [CONTACT_430596] s creening process. Prospective participants will 
have a subjective memory complaint and/or demonstrate memory impairments during 
screening, will be considered ‘sedentary’ as assessed by [CONTACT_430597], will meet all other inclusion/exclusion crite ria, and will agree to be randomized to either the SBR or AX group. 
Study candidates may provide verbal consent over the telephone to complete the EXERT TAPA 
and other screening questions  regarding demographics, medical history, and medications  to 
assess e ligibility for continued screening, if permitted by [CONTACT_1036]. Study candidates and 
ADC-041-EX   Page 39 of 78 
 
 Version 7.0: 18NOV2021 
   
 their collaterals  will not be considered as EXERT participants until the core study consent form 
is signed  at an in-person screening visit. 
 
 Screening II (Visit  1) 
 
This assessment will  determine eligibility  to enroll in EXERT, and may be conducted over 
multiple days . Potential participants and their study partners must sign an informed consent 
form (ICF)  and Health Insurance Portability and Accountability Act (HIPAA ) authorization prior to 
administration of any procedures  for this assessment. Screening II procedures will include the 
following:  
 
• ICF/HIPAA: participant and study partner  
• Review of inclusion/exclusion criteria (includes review of EXERT TAPA responses ) 
• Demographics  review  
• Medical history  
• Medication review  
• Brie f physical examination, vital signs, weight, height 
• Brief neurological examination  
• Modified Hachinski   
• Blood collection for ApoE g enotypi[INVESTIGATOR_007], and DNA b anking  
• Blood collection for clinical labs  
• 12-lead resting ECG  
• Cognitive assessment  
o 3MSE/MMSE  
o Logical Memory  I and II  
o Auditory Verbal Learning Test (AVLT)  
• Behavioral/functional assessment 
o CDR  
o Cognitive Change Index (self-administered)  
o GDS (self -administered)  
• [ADDRESS_544618] 
• Brain MRI  
o For participants meeting all other eligibility criteria (as determined by [CONTACT_163399] ) 
o Participants may be excluded from enrollment if safety concerns are identified  
o At approved sites, protocol will include EXERT fMRI sequences  
• Dispense ActiGraph Link for actigraphy data collection  
o Dispense following completion of screening procedures to participants who meet 
eligibility criteria and thus are at high probability of randomization 
o Device should be placed on the participant’s non-dominant wrist at the clinic  to 
initiate the recording period 
o Device should continuously remain on the participant’s wrist for the duration of the 10-day recording period 
ADC-041-EX   Page 40 of 78 
 
 Version 7.0: 18NOV2021 
   
 o Retrieve ActiGraph Link device 10 days later during a baseline visit or by [CONTACT_2319] 
(with a reminder call on Day 10), and upload data  
o Data collection should be completed prior to randomization 
 
The participant will be permitted to proceed to the baseline visit if all inclusion/exclusion criteria 
are met, results from all screening procedures are  reviewed, and eligibility have been approved 
by [CONTACT_6962]. The PDs, in consultation with the ADCS Medical Director, must approve any exceptions or questions regarding possible exclusionary medications, medical conditions, or laboratory tests.  In addition, the PDs must approve any exceptions to cognitive eligibility criteria in cases where there is compelling evidence for MCI but not all cognitive eligibility criteria are met.   The baseline visit should be scheduled within [ADDRESS_544619] occur more than 90 days later. If the baseline visit is 
scheduled more than 6 weeks from Screening II (i.e., out-of -window), approval to proceed to the 
baseline visit must be obtained from the ADCS and a rescreen may be requir ed.  
 
 Baseline (Visit  2) 
 
Baseline procedures  may be completed over multiple days, but all assessments should be 
completed within [ADDRESS_544620]  be 
completed before randomization and start of exercise, and include: 
 
• Review of i nclusion and exclusion criteria 
• Medic ation review  
• Vital s igns, weight 
• Fasting blood collection for banking  
• AE q uery 
• Cognitive as sessment 
o Primary o utcomes assessment (administer the following tests before 
administering other cognitive/behavioral instruments)  
 ADAS- Cog13 
 Trail-Making Test  
 DSST 
 Category and Letter Word Fluency  
o Secondary outcomes assessment (iPad  computer tests ) 
 Cogstate: Detection task (DET ), Identification task (IDN) , One Card 
Learning (OCL) , One Back task (OBK), Groton Maze Learning Test 
(GMLT) , Face Name [CONTACT_430630]  (FNAME) , Behavioral 
Pattern Separation of Objects  (BPSO)  
 NIH Toolbox : Flanker, Dimensional Change Card Sort (DCCS)  
• Behavioral/functional and other outcomes assessments 
ADC-041-EX   Page 41 of 78 
 
 Version 7.0: 18NOV2021 
   
 o Staff-administered questionnaires 
 ADCS -ADL-MCI 
 BRIEF-A 
 NPI 
o Self-administered questionnaires 
 By [CONTACT_3445] 
 SF-36 
 EQ5D  
 Research Satisfaction Survey  
 By [CONTACT_402291]  
 Study Partner Self-Assessment Questionnaire (SF-36, 
Pi[INVESTIGATOR_2272] , Insomnia Severity Index , 
questions regarding healthcare utilization)  
 EQ5D  (as it relates to participant)  
• LP 
o For participants who agree to the LP  
o Follow -up telephone call by [CONTACT_430598] 24 hours to query AEs  
• Randomization 
o Eligible p articipants will be randomized to either the SBR or AX group centrally 
by [CONTACT_430599] a real -time web-based randomization system  
o Designated unbl inded clinic staff member will disclose this assignment to the 
participant, in person, when all baseline assessments have been completed 
o Participants will be provided with a packet of materials describing their assigned 
intervention, their responsibilities to the study, and what the study will provide for 
them . At a YMCA appointment, Trainers will provide participants with a HR 
monitor, the first Physical Activity Log, and the appropriate Activity Resource 
Guide. 
o Participants will be instructed to maintain their regular diet and other activities for 
the duration of the study   
o At time of disclosure, and once the provided materials have been carefully 
reviewed with the participant, the participant will be asked to sign a document 
indicating his/her willingness to complete the assigned programs as instructed, 
for the duration of the [ADDRESS_544621] baseline visit 
o Participants will be instructed to withhold all information about intervention group 
assignment from  all other clinic staff members throughout study participation; the 
importance of keepi[INVESTIGATOR_430516] ‘secret’ will be emphasized and discussed  
• At Site PI [INVESTIGATOR_9106], an optional letter can be provided to notify the participant’s primary 
care physician of participant enrollment in the study.  
 
ADC-041-EX   Page 42 of 78 
 
 Version 7.0: 18NOV2021 
   
 Beginning in Month 1, Clinic YMCA Liaison will complete a monthly telephone call to query AEs, 
obtain medication updates, provide encouragement, and problem -solve challenges to continued 
participation.  
 
 Month 6 (Visit 3) 
 
The Month 6 assessment should be completed 6 months (+/- 2 weeks) from the participant’s 
first appointment at the YMCA that initiated the intervention. Participants will be  asked to bring 
their HR monitor to the appointment and to refrain from exercise for 24 hours prior to cognitive 
testing, which should not be completed while participants are fasting. Month 6 procedures 
include:  
 
• Fasting blood collection for banking  
• Medication review  
• Brief physical exam, vital signs, weight 
• Brief neurological exam  
• AE query  
• Briefly review adherence with participant using report provided through EDC  and entries 
in the Physical Activity Logs (adherence will be regularly monitored by [CONTACT_430600], the Y -PM and the Intervention Oversight Team  as well ) 
• Cognitive as sessment 
o Primary outcomes assessment (administer the following tests before 
administering other cognitive/behavioral instruments)  
 ADAS- Cog13 
 Trail-Making Test  
 DSST 
 Category and Letter Word Fluency  
o Secondary outcomes assessment (iPad computer tests ) 
 Cogstate: DET, IDN, OCL, OBK , GMLT , FNAME , BPSO  
 NIH Toolbox: Flanker, DCCS  
• Be havioral/functional and other outcomes assessments 
o Staff-administered questionnaires 
 CDR  
 ADCS -ADL-MCI 
 BRIEF-A 
 NPI 
o Self-administered questionnaires   
 By [CONTACT_3445] 
 Cognitive Change Index  
 SF-36 
 EQ5D  
 Research Satisfaction Survey  
 By [CONTACT_430601]-041-EX   Page 43 of 78 
 
 Version 7.0: 18NOV2021 
   
  Study Partner Self-Assessment Questionnaire (SF-36, 
Pi[INVESTIGATOR_2272], Insomnia Severity Index) 
 EQ5D  (as it relates to participant)  
• [ADDRESS_544622] 
• Dispense ActiGraph Link for actigraphy data collection  
o Place device on the participant’s non-dominant wrist to initiate recording period 
o Device should continuously remain on the participant’s wrist for the duration of 
the 10-day recording period 
o Retrieve device from participant 10 days later by [CONTACT_430602] (with a reminder call on Day 10), and upload data when device is received 
• Replace battery in HR monitor 
• Provide participant with 6-month supply of Physical Activity Logs  
 The Clinic YMCA Liaison will continue to complete monthly telephone calls to query AEs, obtain 
medication updates, provide encouragement, and problem -solve challenges to continued 
participation.  
 
 Month 12 (Visit 4) / or Early Termination 
 
The Month 12 assessment will provide the primary endpoints to evaluate trial efficacy, and 
should be completed 12 months (+/- 2 weeks) from  the participant’ s first appointment at the 
YMCA that initiated the intervention. The following procedures  may be completed over multiple 
days, but within a 7-day window. Participants will be instructed to bring their HR monitor to the 
appointment and to refrain from exercise for 24 hours prior to cognitive testing, fMRI (for 
approved sites), and the LP. Cognitive testing should not be completed while participants are 
fasting, and if conducted after an LP, testing must be administered at least 48 hours following the procedu re. Month 12 procedures include:  
 
• Fasting blood collection for clinical labs  
• Fasting blood collection for banking  
• Medication review  
• Brief physical exam, vital signs, weight 
• Brief neurological exam  
• AE query  
• Briefly review adherence with participant using report provided through EDC  and entries 
in the Physical Activity Logs (adherence will be regularly monitored by [CONTACT_430600], the Y -PM and the Intervention Oversight Team  as well ) 
• Cognitive as sessment 
o Primary outcomes assessment (administer the following tests before 
administering other cognitive/behavioral instruments)  
 ADAS- Cog13 
 Trail-Making Test  
 DSST 
 Category and Letter Word Fluency  
ADC-041-EX   Page 44 of 78 
 
 Version 7.0: 18NOV2021 
   
 o Secondary outcomes assessment  
 3MSE/MMSE  
 iPad computer tests  
 Cogstate: DET, IDN, OCL, OBK , GMLT , FNAME, BPSO  
 NIH Toolbox: Flanker, DCCS  
• Behavioral/functional and other outcomes assessments 
o Staff-administered questionnaires 
 CDR  
 ADCS -ADL-MCI 
 BRIEF -A 
 NPI 
o Self-administered questionnaires  
 By [CONTACT_3445] 
 Cognitive Change Index  
 SF-36 
 EQ5D  
 Research Satisfaction Survey  
 By [CONTACT_430603] 
 Study Partner Self-Assessment Questionnaire (SF-36, 
Pi[INVESTIGATOR_2272], Insomnia Severity Index) 
 EQ5D (as it relates to participant)  
• [ADDRESS_544623] 
• Brain MRI  
o At approved sites, protocol will include fMRI sequences  
• LP 
o CSF may be collected at this visit, even if not successfully collected at Baseline  
o Follow -up telephone call by [CONTACT_430598] 24 hours to query AEs  
• Dispense ActiGraph Link for actigraphy data collection  
o Place on the participant ’s non-dominant wrist to initiate recording period  
o Device should continuously remain on the participant’ s wrist for the duration of 
the 10-day recording period 
o Retrieve device from participant 10 days later by [CONTACT_430602] (with a reminder call 
on Day 10), and upload data when device is received 
• Replace battery in HR monitor 
• Provide participant with 6-month supply of Physical Activity Logs  
• Site PI [INVESTIGATOR_430517] s to complete Treatment Blinding Questionnaire  
 
All participants will transition to unsupervised exercise during the last [ADDRESS_544624] participants by 
[CONTACT_756], once per month to query AEs, obtain medication updates, provide encouragement, 
and problem -solve challenges to continued participation.   
 
ADC-041-EX   Page 45 of 78 
 
 Version 7.0: 18NOV2021 
   
 
 Month 18 (Visit 5) 
 
The Month 18 assessment should be completed 18 months (+/- 2 weeks) from the participant’s 
first appointment at the YMCA that initiated the intervention. Participants will be instructed to 
bring their HR monitor to the appointment and to refrain from exercise for 24 hours prior to 
cognitive testing, which should not be completed while fasting. Participants should also be 
asked to return all Physical Activity Logs for review and data entry, as this will be their final 
EXERT assessment. Month 18 procedures include: 
 
• Fasting blood collection for clinical labs 
• Fasting blood collection for banking  
• Medication review  
• Brief physical exam, vital signs, weight 
• Brief neurological exam  
• AE query  
• Review returned Physical Activity Logs to ensure that they were completed and 
accurately reflect YMCA attendance records (provided in advance) and the participant’s self-report  
• Dispense ActiGraph Link for actigraphy data collection  
o Send device and instructions to participants 14 days before t he Month 18 
assessment; confirm with participant that the device was received and in place 
with a phone call  at the start of the recording period  
o At the clinic visit , remove the device from the participant’s wrist and upload data  
• Cognitive as sessment 
o Primary outcomes assessment (administer the following tests before 
administering other cognitive/behavioral instruments)  
 ADAS- Cog13 
 Trail-Making Test  
 DSST 
 Category and Letter Word Fluency  
o Secondary outcomes assessment (iPad computer tests ) 
 Cogstate: DET, IDN, OCL, OBK , GMLT , FNAME, BPSO   
 NIH Toolbox: Flanker, DCCS  
• Behavioral/functional and other outcomes assessment 
o Staff-administered questionnaires 
 CDR  
 ADCS -ADL-MCI 
 BRIEF-A 
 NPI 
o Self-administered questionnaires  
 By [CONTACT_3445] 
 Cognitive Change Index  
 SF-36 
 EQ5D  
ADC-041-EX   Page 46 of 78 
 
 Version 7.0: 18NOV2021 
   
  Research Satisfaction Survey  
 By [CONTACT_402291] 
 Study Partner Self-Assessment Questionnaire (SF-36, 
Pi[INVESTIGATOR_2272], Insomnia Severity Index) 
 EQ5D (as it relates to participant)  
• [ADDRESS_544625] 
• Provide study close-out materials  
o Summary of progress in  intervention 
o Fasting clinical blood test results  from all visits  
o Color printout of single brain MRI image if available  
o Study completion certificate 
o ‘Thank -you’ gift or payment for participation  
o Participant’s HR monitor  (change battery)  
o Contact [CONTACT_19297] a YMCA staff member who will provide a personal 
coaching session at the YMCA , at no cost  
• Site PI [INVESTIGATOR_430518]  
 
10.0 EARLY INTERVENTION DISCONTINUATION  
 
Investigators  at each site will make every effort to maximize participant retention. If a participant 
expresses a desire to stop the intervention, the Intervention Oversight Team  will be notified and 
will hold a conference call with the Clinic YMCA Liaison and/or site i nvestigator, and Y-PM 
and/or Trainer to discuss the participant’s existing challenges and possible approaches to 
reduce burden to encourage continued participation if at all possible (e.g., adapt exercise 
routine to reduce pain or increase interest, problem -solve regarding transportation issues, etc.).  
 If a participant continues to decline further participation, or if an investi gator discontinues the 
intervention, an Early D iscontinuation Visit should be completed as soon as possible just prior to 
or immediately following intervention discontinuation. The Early Discontinuation Visit will include 
all Month 12 assessments to permit collection of primary and secondary outcome measures. If 
this Early Discontinuation Visit occurs before the start of Month 4, then the MRI and LP (when 
applicable) should not be completed. Alternatively, if an in-person Early Discontinuation Visit 
cannot be completed, site personnel should complete, by [CONTACT_756], as many of the Month 12 
procedures as possible (e.g., medication review, AE query, request return of Physical Activity 
Logs for review and data entry, CDR, Cognitive Change Index, SF-36, ADCS -ADL -MCI, B RIEF -
A, NPI, Research Satisfaction Survey, EQ5D, Study P artner Self-Assessment Questionnaire). 
 
All early intervention discontinuation participants will be strongly encouraged to complete not only the Early Discontinuation Visit, but also all regular ly scheduled clinic assessmen ts through 
Month 18.   
  
ADC-041-EX   Page 47 of 78 
 
 Version 7.0: 18NOV2021 
   
 
 Reasons for Early Discontinuation 
 
Reason(s) for intervention discontinuation will be coded as follows : 
 
• Perceived lack of efficacy  by [CONTACT_3445]  
• Adverse experience by [CONTACT_430604], in the opi[INVESTIGATOR_871], requires 
early termination; this may include abnormal laboratory values  
• Participant becomes a safety risk   
• Death 
• Participant is unwilling or unable to participate 
• Participant is not able to adhere to protocol requirements as per judgm ent of the 
Intervention Oversight Team or site investigator  
• Study partner unwilling or unable to participate, and new appropriate study 
partner cannot be identified 
• Lost to follow up: Participant could not be recalled to the clinic for follow-up assessment s 
• Participant enrolls in another intervention trial 
• EXERT is terminated  
• Investigator  judgment  that it is in the participant’s best interest to discontinue 
participation  
• ADCS request: the ADCS determines that it is in the participant’s best interest to 
discontinue participation in the study  
• Intervention Oversight Team request : the Intervention Oversight Team determines 
that it is in the participant’s best interest to discontinue participation in the study  
 
11.0 STUDY -SPECIFIC INSTRUMENTS   
 
 EXERT Telephone Assessment of Physical Activity  
 
The TAPA is a brief, validated, and commonly  administered telephone-based measurement tool 
to assess phy sical activity in older adults .87 This protocol uses a modified version, adapted for 
EXERT with permission of the original authors.  
 
 Cognitive Evaluations  
 
11.2.1 Modified Mental State Examination  
 
The 3MSE, an expanded version of the MMSE, has been widely used in epi[INVESTIGATOR_430519].88 The 3MSE consists of items assessing 8 domains 
of cogniti ve function (remote memory, recent memory, mental control, time and space 
orientation, abstract thinking, verbal abilities, verbal comprehension and spatial cognition) and i s 
scored on a 100-point scale with higher scores indicating better performance. The MMSE89 is a 
ADC-041-EX   Page 48 of 78 
 
 Version 7.0: 18NOV2021 
   
 brief, frequently used screening instrument for AD  drug studies  and i ncludes several shared 
items with the exp anded version.  
 
11.2.2 Logical Memory  
 
Logical Memory I and II (immediate and delayed recall) is a modification of the epi[INVESTIGATOR_430520]-Revised (WMS -R).
90 In this version, free recall of one 
short story consisting of 25 bits of information will be elicited immediately after it is read aloud to 
the participant and again after a 20-30 minute delay. Total  bits of information from the story that 
are recalled immediately (maximum score = 25) and after the delay (maximum score = 25) are recorded.   
11.2.[ADDRESS_544626] (Trial 6). Following 
a 20-30minute delay filled with unrelated testing, free recall of the first 15- item word  list (Trial 7) 
is again elicited.  
 11.2.[ADDRESS_544627] box scores .
49 
 ADAS- Cog13.  The ADAS -Cog
92 is a structured scale that evaluates memory (word recall, word 
recognition), reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). Ratings of spoken language, language comprehension, word finding difficulty, and ability to remember test instructions are also obtained. The test is scored in terms of errors, with higher scores reflecting poorer performance and greater impairment. Scores can range from 0 (best) to 70 (worse) and then number of items not recalled ranging from 0-[ADDRESS_544628] (Trails A and B). Trails A
[ADDRESS_544629] the circles in ascending numerical order as quickly as possible (150 second maximum). Trails  B 
consists of 25 circles containing either numbers (1 through 13) or letters (A through L)  that are 
randomly distributed across the page, and participants are instructed to connect the circles in 
alternating and ascending order  (e.g., 1 to A; 2 to B). Time to complete Trails B (300 second 
maximum), adjusted for the time taken to complete Trails  A to control for sensorimotor demands  
ADC-041-EX   Page 49 of 78 
 
 Version 7.0: 18NOV2021 
   
 of the task, is a sensitive measure of executive function and working memory, and the effects of 
aerobic exercise.16,[ADDRESS_544630].  The DSST89 is a subset from the Wechsler Adult Scale of 
Intelligence-Revised (WAIS-R).  The test consists of 110 small blank squares presented in 7 
rows with 1 of 9 numbers (1-9) randomly printed directly above each blank square. A legend is 
printed above the rows of blank squares, at the top of the page. The legend pairs  each of the 
numbers with an abstract symbol. Following a few  practice trials, the participant is asked to use 
the legend to fill in the blank squares in consecutive order, working from left to right across the 
rows , with the symbol that is paired with each number and as quickly as possible for [ADDRESS_544631] is recorded (maximum score =110). This test engages multiple 
abilities including attention, psychomotor speed, visual  scanning and tracking, and working 
memory.  The ADAS- Cog-Exec global composite scale includes the total score for the Digit 
Symbol Substitution Test.  
 
Word Fluency . This 2-part task assesses word fluency  by [CONTACT_430605], and thus  
involves planning, organiz ation, and cognitive flexibility. Participants are asked to generate as 
many words as possible in 60 seconds that begin with different letters of the alphabet (f and L), 
in 2 separate trials. Participants are then asked to generate as many words as possible in 60 
seconds that belong to a  given semantic category ( animals , vegetables). Reduced word fluency 
is associated with AD  onset and progression,93 and was sensitive to the effects of aerobic 
exercise in preliminary studies.16,20 The ADAS -Cog-Exec global composite includes the score 
for Category Fluency (mean of Animal and Vegetable Fluency).  
 Clinical Dementia Rating Scale – Sum of Boxes . The CDR
89 is a clinical scale that rates the 
severity of dementia as absent, questionable, mild, moderate, or severe (CDR score of 0, 0.5, 1, 2, or 3, respectively). The score is based on interviews with the participant and study partner, using a structured interview that assesses 6 domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The ratings of degree of impairment for each of the 6 domains are synthesized into one global rating of 
dementia (ranging from 0 to 3), with more refined measure of change available with the Sum of Boxes. At screening, the CDR global and memory scores will be used to assess eligibility. For 
all other administrations, scores across the [ADDRESS_544632] Memory, Orientation, and 
Judgement and Problem Solving.  
 
11.2.5 Executive Function Composite 
 
The Executive Function C omposite will combine  8 measures of executive control using 
performance outcomes on paper -and-pencil tests ( described above: Trails B, DSST , Word 
Fluency, Number Cancellation), and iPad tests from the NIH Toolbox (Flanker, DCCS), and 
A D C -0 4 1 -E X   P a g e 5 0  of 7 8  
 
 V er si o n 7. 0: [ADDRESS_544633] at e ( G M L T, O B K ). NI H T o ol b o x a n d C o g st at e t e st s will b e l o a d e d o n t h e s a m e i P a d a n d 
a c c e s s e d t hr o u g h diff er e nt i c o n s  o n t h e s cr e e n .  NI H T o ol b o x  Fl a n k er.
[ADDRESS_544634] m e a s ur e s att e nti o n a n d i n hi bit or y c o ntr ol. T h e 
p arti ci p a nt i s a s k e d t o f o c u s o n o n e sti m ul u s ( arr o w i n t h e c e nt er of t h e s cr e e n ) w hil e i n hi biti n g 
at t e nti o n ot h er sti m uli (fl a n ki n g arr o w s). S o m eti m e s t h e c e ntr al sti m ul u s i s p oi nti n g i n t h e s a m e 
dir e cti o n a s t h e fl a n k er s ( c o n gr u e nt) a n d s o m eti m e s i n t h e o p p o sit e dir e cti o n (i n c o n gr u e nt). S c ori n g i s b a s e d o n a c o m bi n ati o n of r e a cti o n ti m e  a n d a c c ur a c y. T h e t e st t a k e s a p pr o xi m at el y [ADDRESS_544635] s of c o g niti v e fl e xi bilit y ( i. e., C ol or-W or d I nt erf er e n c e I n hi biti o n  of t h e D eli s -
K a pl a n E x e c uti v e F u n cti o n S c al e s). I n t hi s s p e e d e d t e st, [ADDRESS_544636] ur e s ar e pr e s e nt e d t h at 
v ar y al o n g 2 di m e n si o n s ( i. e., s h a p e, c ol or). P arti ci p a nt s ar e a s k e d t o m at c h a s eri e s of bi v al e nt 
t e st pi [INVESTIGATOR_211168] e s ( e. g., y ell o w b all s, bl u e tr u c k s) t o t h e t ar g et pi [INVESTIGATOR_211168] e s, fir st a c c or di n g t o o n e 
di m e n si o n ( e. g., c ol or) a n d t h e n, aft er a n u m b er of tri al s, a c c or di n g t o t h e ot h er di m e n si o n ( e. g., s h a p e). “ S wit c h” tri al s ar e al s o i n cl u d e d, i n w hi c h t h e p arti ci p a nt m u st c h a n g e t h e di m e n si o n b ei n g m at c h e d. F or e x a m pl e, aft er [ADDRESS_544637]  (P e di atri c V er si o n ).
[ADDRESS_544638] of e x e c uti v e 
f u n cti o n a s s e ssi n g vi s u al/ s p ati al  w or ki n g m e m or y, l e ar ni n g, a n d err or m o nit ori n g.  T h e t e st c o n si st s of a n [ADDRESS_544639] a rti n g i n t h e t o p l eft 
c or n er,  a n d r e s p o n d s t o f e e d b a c k a b o ut w h et h er t h e t o u c h e d til e b el o n g s t o t h e p at h, w hi c h i s 
i n di c at e d b y a ‘
� �’ if c orr e ct, a n d a n ‘X ’ if i n c orr e ct. If t h e m o v e i s c orr e ct, t h e � �r e m ai n s vi si bl e o n 
t h e til e a n d t h e p arti ci p a nt t o u c h e s  a n ot h er a dj a c e nt s q u ar e. If t h e t o u c h i s i n c orr e ct, t h e X  o n 
t h e til e di s a p p e ar s a n d p arti ci p a nt s m u st t o u c h t h e l a st c orr e ct til e i n t h e p at h  b ef or e c o nti n ui n g. 
T h e tri al e n d s o n c e t h e p arti ci p a nt s u c c e s sf ull y t o u c h e s all til e s i n t h e hi d d e n p at h t h at l e a d s t o 
t h e fl a g i n t h e b ott o m ri g ht c or n er of t h e gri d. T ot al ti m e f or t e st a d mi ni str ati o n i s a p pr o xi m at el y [ADDRESS_544640] er all 3 t a s k s i s 6 
mi n ut e s ( 2 mi n ut e s p er t a s k). 
  
ADC-041-EX   Page 51 of 78 
 
 Version 7.0: 18NOV2021 
   
 11.2.[ADDRESS_544641] Recall from the ADAS -Cog13 and four Cogstate tasks  administered via iPad  
(FNAME, BPSO, OCL, GMLT- Delayed Recall) . 
Cogstate Face-Name [CONTACT_311682] . FNAME [CONTACT_188234] [ADDRESS_544642] names  (5 lis ts of 36 trials) , and engages memory networks , including the 
hippocampus and default network regions  as per fMRI findings.97-99 During encoding, 
participants are instructed to remember each face-name [CONTACT_430631] ‘fits’ the face  using a Likert scale. During retrieval , participants are 
asked to recall the correct name [CONTACT_430632], and subsequently, to select the 
correct name [CONTACT_430633]. For both tasks, a ccuracy is 
recorded. Test performance is  sensitive to physical activity in older adults.[ADDRESS_544643] 
displays pi[INVESTIGATOR_430521] “ lures” 
that vary in levels of mnemonic and visual similarity with target items. During encoding, 
participants indicate whether pi[INVESTIGATOR_430522] “indoor” or “outdoor” objects by [CONTACT_354133] a ‘button’ 
on the screen. During the test phase, participants view objects that include exact replicas  of 
previously viewed objects, similar but not identical objects, and new objects, and are asked to 
judge whether each object is  “old,” “similar,” or “new” using a ‘button’ press. Higher accuracy  
reflects b etter separation of the visual patterns, and thus better memory. The B PSO robustly 
activates the hippocampus in fMRI studies, and is sensitive to early dysfunction in the hippocampus in aging,
102-[ADDRESS_544644] OCL performance for simple and choice 
reaction time.   
Cogstate GMLT -Delayed Recall . Free recall of the previously learned hidden path will be 
assessed following a delay of approximately 15 minutes. 
 
 Behavioral and Functional Evaluations  
 11.3.1 Clinical Dementia Rating Scale – Sum of Boxes (described above)  
 
11.3.[ADDRESS_544645] functiona l decline in adults  with MCI.
109 It was adapted from an inventory 
developed by [CONTACT_430606].110 In a structured 
ADC-041-EX   Page 52 of 78 
 
 Version 7.0: 18NOV2021 
   
 interview, study partners are queried as to whether participants attempted each item in the 
inventory during the prior 4 weeks and at what ‘ level’ of performance. The questions focus 
predominantly on instrumental activities of daily living (e.g. shoppi[INVESTIGATOR_007], preparing meals, usi ng 
household appliances, keepi[INVESTIGATOR_55228], reading).  
 
11.3.3 Behavior Rating Inventory of Executive Function – Adult Version  
 
The BRIEF- A is a standardized and validated questionnaire that captures subjective report o f an 
adult’s executive function or self-regulation in an  everyday environment. The questionnaire can 
be administered to obtain self- or informant-report .  
 
11.3.4 Neuropsychiatric Inventory   
 
The NPI [CONTACT_832] a well -validated, reliable, multi -item instrument to assess psychopathology in MCI 
and AD dementia based on the results of an interview with the study partner .111 The NPI 
[INVESTIGATOR_430523] 10 neuropsychiatric features, including delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition irritabili ty 
and lability, and aberrant motor behavior, as well as evaluates sleep and appetite/eating 
disorders. Frequency assessments range from 1 (occasionally, less than once per week) to 4 
(very frequently, once or more per day or continuously). Severity assessments range from 1 (mild) to 3 (severe). The score for each subscale is the product of severity and frequency and the total score is the sum of all subscales.  
 
11.3.5 Cognitive Change Index  
 
The Cognitive Change Index, adapted from Saykin et al.,
112 is a self-report questionnaire listing 
common experiences (e.g., “recalling conversations a few days later ”, “remembering names and 
faces of new people I meet”) and participants indicate amount of perceived change over the 
past [ADDRESS_544646] 12 questions that address subjective memory 
concerns will be administered. The same 12-item subscale is used in the large multicenter 
ADNI -2 study.  
 11.3.6 Geriatric Depression Scale  
 The GDS  is a well -validated, self-administered questionnaire used to assess mood in geriatric 
populations.
113  
 
11.3.7 SF-36  
 
The Short Form Health Survey is a well -validated, commonly used self- administered survey of 
health status  that includes questions about mood, pain, physical functioning, and overall 
health.114 
 
  
ADC-041-EX   Page 53 of 78 
 
 Version 7.0: 18NOV2021 
   
 11.3.8 EQ5D  
 
The EQ5D is a brief questionnaire about health- related quality of life that queries 5  dimensions  
of everyday experience (mobility, self-care, usual activities, pain/discomfort, anxiety/depression)  
that are each rated using a 5-point scale (no problems/slight problems/moderate problems/severe problems/extreme problems) . The EQ5D is a wel l-validated instrument that 
provides a single index for overall health status .
115 
 
11.3.9 Study Partner Self -Assessment Questionnaire 
 
This self -administered questionnaire assesses the study partner’s mood, physical functioning, 
sleep, and overall health status, and includes the SF-36 (described above)  and 2 well -validated 
brief assessments of sleep quality (Pi[INVESTIGATOR_2272] ) and duration (Insomnia 
Severity Index116). 
 
 Modified Hachinski 
 
This brief questionnaire, conducted by a clinician,  incorporates information regarding medical 
history, cognitive symptoms and features of stroke, reported by a study partner as well as the 
neurological examination, and neuroimaging studies .[ADDRESS_544647] studies show  that participant input and feedback is important for 
retention.
118,119 
 
 Treatment Blinding Questionnaire 
 Following the Month 12 and 18 clinic assessments, the site PI [INVESTIGATOR_430524] a Treatment Blinding Questionnaire to document knowledge of intervention group assignment per 
participant.  
 
 
  
ADC-041-EX   Page 54 of 78 
 
 Version 7.0: 18NOV2021 
   
 
 Heart Rate Monitor  
A HR monitor that includes a watch -like device and a chest 
strap will be provided to all participants to wear during exercise, 
which will pe rmit HR monitoring to assess effort and exercise 
intensity.   
 ActiGraph Link 
 
The ActiGraph Link is a validated 3-axis accelerometer and 
watch-like device (ActiG raph™) with a low profile case and 
high-resolution liquid crystal display window (see pi[INVESTIGATOR_1103] o n 
right). The device contains a gyroscope, magnetometer, and 
secondary accelerometer to record movement, rotation, and body position data. The ActiGraph Link will be configured to 
display only the time, not activity information.   
 Instruments Administered by [CONTACT_430607]  
 
11.9.1 Rating of Perceived Exertion  
 
The RPE modified Borg scale is a validated and accepted supplemental method for assessing exercise intensity in older adults. The rating scale ranges from 1 to 10 (1 =very mild, to 10 
=very, very hard), and participants are trained to self-assess their cardiorespi[INVESTIGATOR_430525].  
 
11.9.[ADDRESS_544648] week, and will include questions to identify SAEs (death, life-threatening, hospi[INVESTIGATOR_059], disability or permanent damage). 
 
12.0 STUDY –SPECIFIC PROCEDURES  
 
 Safety Assessments 
 
Physical  and neurological examination s will occur every 6  months while participants are enrolled 
in the study . An MRI will be conducted during screening and repeated at Month 12 for safety 
assessment  and study outcomes . Participants receiving an LP will receive a follow-up telephone 
call 24 hours later from the clinic to confirm the participant’s well-being and to query AEs, which 
will be reported to the ADCS DSMB. Safety  reports will be prepared by [CONTACT_430608].  
 

ADC-041-EX   Page 55 of 78 
 
 Version 7.0: 18NOV2021 
   
 Participants will  exercise at YMCA facilities staffed by [CONTACT_430609]. Twice per week, a study -certified YMCA Trainer will supervise the 
participant while exercising to ensure safe practices are consistently used.   
 
12.1.[ADDRESS_544649] 12-lead resting ECG will be performed during s creening. The ECG report will be 
reviewed, signed, and dated by [CONTACT_093]. Those with clinically significant ECG findings 
will be referred for follow -up as deemed appropriate by [CONTACT_093] , and may be excluded 
from the study . 
 
12.1.3 Clinical Laboratory Evaluations 
 
All routine laboratory samples will be analyzed by a central laboratory, which will provide a procedures manual and supplies. Lab reports will be reviewed, signed and dated by [CONTACT_430610] . If a value is outside of the laboratory’s normal range, the Study Clinician will indicate if 
it is clinically significant. If clinically significant, lab tests may need to be repeated and/or follow -
up with the participant’s PCP may be required.    
 Clinical laboratory assessments include: 
• Chemistry Panel (Screening II, Month 12)  
• Fasting glucose and hemoglobin A1c  
• TSH (Screening II)  
• CBC | Differential (Screening II, Month 12)  
• Vitamin B12 (Screening II); Note: HCY & MMA reflex tests will be run only if the B 12 
level is ≤211 pg/ml; additional blood draw will not be required for reflex testing 
• PT, PTT Coagulation Panel (Screening II, Month 12)  
 
  
ADC-041-EX   Page 56 of 78 
 
 Version 7.0: 18NOV2021 
   
 
 Biofluids 
 
Biofluid collection schedule, quantities, and assessments are summarized in the table below.  
 
12.2.[ADDRESS_544650] plasma and peripheral blood mononuclear cells (PBMCs) in the 
morning after a minimum 10-hour overnight fast, and shipped to the ADCS Biomarker Core at 
UCSD for banking and analysis .  
 
12.2.[ADDRESS_544651]. Participants who are taking anticoagulants, warfarin (Coumadin) and 
dabigatran (Pradaxa) should not be screened for an LP, as these are prohibited medications. Based on clinician judgment and depending on the clinical indication, it may be suitable to discontinue participants from their anti -platelet agent (e.g., aspi[INVESTIGATOR_248], Plavix , NSAIDs) for [ADDRESS_544652] 24 hours after the procedure . It is not required that participants 
be discontinued from their anti -platelet agent in order to screen and enroll in EXERT .  
 

ADC-041-EX   Page 57 of 78 
 
 Version 7.0: 18NOV2021 
   
 The baseline LP must be conducted prior to randomization. At Month [ADDRESS_544653] 1-2 mL of CSF are discarded (or more if needed) . 
Collected CSF will be aliquoted into sterile microtubes . Approximately 2 mL of CSF or volume 
per local laboratory requirements will be sent at ambie nt temperature to the local laboratory for 
protein, glucose and cell count. The remaining CSF will be shipped to the ADCS Biomarker 
Core  at UCSD  for storage and analysis. 
 
 Magnetic Resonance Imaging   
 
12.3.1 Site Qualification  
 
Structural MRI. All sMRI procedur es will be overseen by [CONTACT_430611]. Each site’s 
scanner will have an identifying number, which will be appended to the image header of all MRI 
data. Each scanner will be subjected to a qualifying process that includes an evaluation for excessive vibration or other image artifact revealed through submitted magnetic resonance 
(MR) images obtained through a standard protocol of an American College of Radiology 
phantom. In addition, 3D T1 MPRAGE or IR -FSPGR images of a human brain obtained through 
a standardized imaging protocol of a volunteer at each site will be submitted to the ADCS Imaging Core for automated segmentation, and the resulting segmentations will be examined by 
[CONTACT_430612]. Once the phantom and volunteer scan pass 
quality control by [CONTACT_430611], the scanner will be considered certified for EXERT. 
Because longitudinal analysis of brain volumetry will be used in this study, sites will be required to use the same scanner for both scans (Baseline, Month 12) of a particular participant. 
 
Functional MRI. Arterial Spin Labeling (ASL) is a contrast-free, resting-state fMRI approach to 
quantify regional blood flow in the brain. Sites that are able to perform ASL will be asked to work with the Imaging Core and collaborators at Wake Forest to establish a qualified ASL protocol, which can be appended to the sMRI protocol. ASL will be evaluated and approved centrally in a manner similar to the sMRI qualification procedures described above. Unlike sMRI qualificati on 
for safety and volumetric outcomes, ASL qualification will not be required for initiating study procedures.  
 
12.3.2 Data Acquisition  
 
The same MRI  protocol s will be administered at screening and Month 12, which will include a 
localizer scan, followed by a hi gh-resolution 3D T1 structural series (MPRAGE or IR -SPGR), a 
T2-weighted series (FLAIR), a diffusion weighted scan, and a gradient recalled echo scan. Sites 
with access to approved 3.0 Tesla (3T) scanners will be asked to include a resting-state ASL 
fMRI series that will be appended to the standard ADCS protocol.  
 
ADC-041-EX   Page 58 of 78 
 
 Version 7.0: 18NOV2021 
   
 12.3.[ADDRESS_544654] pass the study’s qualification procedures, and participants must be scanned by [CONTACT_430613] 12. The analysis procedure will include corrections for gradient 
nonlinearities and intensity non-uniformity.
120-122 
 
Sites  will be required to procure a clinical read of each participant’s MRI to confirm eligibility 
based on image-derived inclusion and exclusion criteria. Inconclusive findings will be subject to 
review by [CONTACT_430611]. All imaging data will be de-identified through a numerical 
coding system  and submitted to the ADCS EDC.  
 
 [ADDRESS_544655] and safe means of assessing walking speed and endurance that 
correlates with peak oxygen consumption in older adults,
123 and provides community -based 
translational relevance. The timed walk covers 10 laps totaling 400 m. The will be administered 
by [CONTACT_430614] a standardized protocol that has been validated in a large trials of 
older adults (e.g., LIFE).78,86 In EXERT, participants will not undergo exercise stress testing. The 
American Heart Association and the ACSM joint position statement advised that “apparently healthy persons of all ages and asymptomatic persons at increased risk may participate in moderate-intensity exercise without first undergoing a medical examination or a medically supervised, symptom -limited exercise test”.
[ADDRESS_544656] a high prevalence of ECG abnormalities,125 which diminish the diagnostic 
accuracy of treadmill exercise testing.126 Participants with potential c ardiac contraindications for 
participation in either intervention will be excluded during screening.  
 
  
ADC-041-EX   Page 59 of 78 
 
 Version 7.0: 18NOV2021 
   
 
 Actigraphy  Recordings 
 
Accelerometry data will be collected over a 10-day period at Baseline, and at Months 6, 12, and 18. Participants will continuously wear the ActiGraph Link, a watch-like device, for the entir e 
recording period – even while showering and bathing. It is also important that participants wear 
the device while sleepi[INVESTIGATOR_007] .  
 
During Screening II after the MRI and when the majority of eligibility requirements have been 
confirmed, a clinic staff member w ill initialize the d evice and place it on the participant’s non-
dominant wrist t o start the 10-day recording period. Ten days later (at a minimum ), the device 
should be retrieved from the participant during a baseline visit (preferable) or by [CONTACT_2319] (with a 
reminder call on D ay 10), and the data uploaded using the provided Acti Graph hub. The 
baseline actigraphy recording is to be completed prior to randomization ( highly preferable), but 
most certainly before intervention initiation at the YMCA .  
 For the Month 6 and 12 assessments, the ActiGraph Link should once again be placed on the participant’s non-dominant wrist during the clinic visit to initiate the recording. Participants 
should be reminded to continuously wear the device, even in the shower and while sleepi[INVESTIGATOR_007], for the entire 10 -day period. The device should be retrieved from the participant 10 days later (at a 
minimum) by [CONTACT_430602] , with a reminder call on Day  10, and the data uploaded using the 
provided ActiG raph hub .  
 
For the Month [ADDRESS_544657] at the start of the recording period. At the Month 18 
visit, the device will be removed from the participant’s wrist and the data uploaded using the 
ActiGraph hub. 
 
13.0 PERSONNEL REQUIREMEN TS 
 
Personnel roles and requirem ents to carry out the protocol are listed below. Additional details 
are provided in the procedures manual. 
 
 Clinic Personnel  
 At a minimum, 4 clinic staff members (Site PI/Study Clinician, Study Coordinator/Clinic YMCA 
Liaison, Rater 1, Rater 2) and will be required to carry out the protocol at each site. Additional 
functions are outlined below that may be covered one staff member at some  sites, or multiple 
staff at other sites. 
 
 
• Site Protocol Principal Investigator: [INVESTIGATOR_430526]. The PI [INVESTIGATOR_430527]. The PI [INVESTIGATOR_430528]-041-EX   Page 60 of 78 
 
 Version 7.0: 18NOV2021 
   
 ensure that the Raters maintain a high level of skill and accuracy in conducting 
assessments. If the PI [INVESTIGATOR_430529] C linician  (unblinded) , the PI 
[INVESTIGATOR_430530].  
 
• Study Clinician: The Study C linician will be responsible for conducting and supervising 
the medical evaluation (physical and neurological examinations), ensuring medical eligibility for the study, reviewing AEs, interpreting laboratory results, and supervising 
study -related clinical care provided to the participant. This person will also perform , or 
supervise trained medical staff to perform, the LPs. The Study Clinician may be a 
physician, or if consistent with local practice and regulations, a nurse practitioner or physician’s assistant. The Study Clinician will be reviewing AEs and thus will be 
unblinded to intervention group assignment. 
 
• Study Coordinator: This person will be responsible for managing the day -to-day 
conduct of the trial. Duties may include tracking recruitment, ensuring accurate administration of all instruments at the site, maintaining CRFs , processing of laboratory 
samples, serving as liaison with the ADCS clinical monitor, coordinating clinic visits, 
administering cognitive assessments, and data entry of outcomes other than those associated with intervention adherence. If the Study Coordinator also serves  as the 
Clinic YMCA Liaison  (unblinded), this  person may not be involved in outcomes collection 
or data entry  at any time during the study.   
 
• Clinic YMCA Liaison: This person will serve as the primary liaison between the clinic 
and the participating local YMCA to facilitate bi -directional information exchange 
regarding study and participant progress, and to assist in resolving participant issues as they arise. Thus, this person will be unblinded to intervention group assignment. Duties 
will include monthly visits with the YMCA study team ; monthly telephone calls to 
participants to query progress, AEs, and new medications; and attendance on twice per month calls with the Intervention Oversight Team . This person must not have access to 
cognitive or functi onal data, and thus may not serve as a Rater or be involved in data 
entry of these outcomes  at any time during the study . 
 
• Raters 1 and 2: Raters will be blinded to intervention group assignment, and will be 
responsible for administering the cognitive and functional assessments , and maintaining 
all appropriate certifications. The same individual should not administer both the ADAS -
Cog13 and the CDR. The Raters must be certified to administer the [ADDRESS_544658] study outcomes .  
 
 YMCA Study Team  (see Section 6.2.1) 
 
  
ADC-041-EX   Page 61 of 78 
 
 Version 7.0: 18NOV2021 
   
 14.[ADDRESS_544659] will be faxed to the clinic to permit review and data entry of Study Clinician-verified AEs within 24 hours of reporting, and AE medical management as 
needed. AEs will also be queried at each clinic assessment visit, and during the monthly telephone call by [CONTACT_430575]. 
 
 
 Definition 
 An AE is defined as per the Code of Federal Regulation Title 21 Part 312, http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32
, and refers to 
any health-related unfavorable or unintended medical event that occurs after the informed 
consent is signed. An AE includes  but is not limited to: (1) worsening or change in nature, 
severity, or frequency of conditions or symptoms present at the start of the study; (2) participant deterioration due to primary illness; (3) intercurrent illness; and (4) physical incapacity to carry out the intervention. An abnormal laboratory value will only be reported as an AE if the investigator considers it to be an AE, or if it leads to the discontinuation or termination of the 
intervention.  
 Minor AEs are defined as conditions that may be unpleasant and bothersome to the participant 
such as sore muscles, but do not require intervention discontinuation. Examples of minor AEs include but are not limited to the following: anxiety, fatigue, decreased appetite, insomnia, dizziness, muscle or joint stiffness, muscle strain or soreness, ankle or knee pain, foot pain, and other minor symptoms that may have restricted the participant’s usual activities for at least ½ day like a head cold, flu or allergy problems. Minor AEs should be reported on an annual basis 
to the site IRB.  
 
The investigator should attempt to establish a diagnosis of the event based on signs, symptoms, and or other clinical information. In such cases, the diagnosis should be documented as the AE 
and not the individual signs  or symptoms. Symptoms and conditions present at the beginning of 
the study will be characterized, so that AEs can be defined as any new symptom, or any increase in frequency or severity of an existing symptom. Adverse events should be described 
with medical terminology so that the event can be matched against a medical coding dictionary, such as MedDRA.  
 
  
ADC-041-EX   Page 62 of 78 
 
 Version 7.0: 18NOV2021 
   
 
 Follow -Up of AEs 
 
The Study Clinician will be responsible for review of all AEs. Following questioning and evaluation, all AEs, whether determined to be related or unrelated to the intervention by [CONTACT_430615] , must be documented in the participant’s medical record in accordance with the 
investigator’s normal clinical practice, and on the AE Case Report Form (e-CRF ). Adverse 
events will be rated as mild, moderate or severe, and for duration, severity, seriousness and 
causal relationship to the intervention. This will also pertain to abnormal laboratory values 
deemed clinically significant by [CONTACT_430616].  
 The Study C linician is obliged to follow participants with AEs until the events have subsided, the 
conditions are considered medically stable, or the participants are no longer available for follow up. Participants who discontinue the study due to adverse experiences will be treated and 
followed according to established medical practice. All AEs will be reported to the ADCS DSMB .  
 
 Reporting of Unanticipated Problems, AEs,  Protocol Deviations 
 
Any unanticipated problems, serious and unexpected AEs , deviations or protocol changes will 
be promptly reported by [CONTACT_978] [INVESTIGATOR_1660] a designated member of the research team  to the site IRB , the 
ADCS DSMB, and the sponsor (NIA) if appropriate. 
 
15.0 SERIOUS ADVERSE EVEN TS 
 
 Definition  
 
A SAE is defined as per the Code of Federal Regulation Title 21 Part 312, http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=312.32
, and includes: 
death, a life- threatening adverse experience, inpatient hospi[INVESTIGATOR_6929], a persistent or significant disability/incapacity, or a clinically significant laboratory or clinical test result. Important medical events that may not result in death, be life-threatening, or require hospi[INVESTIGATOR_430531] a more serious outcome listed above, such as an injurious fall resulting in a fracture that occurred while 
comp leting one of the exercise interventions. 
 
 Reporting SAEs  
 
Any SAE due to any cause that occurs during the course of the investigation (i.e., anytime after 
informed consent, regardless of study intervention exposure) must be reported to the c linic and 
the ADCS within 24 hours of learning of the event. All SAEs will be reported to the DSMB, with 
the blind maintained and in summary format (i.e., Group A, Group B).   
  
ADC-041-EX   Page 63 of 78 
 
 Version 7.0: 18NOV2021 
   
 16.[ADDRESS_544660] all data collected (either written or electronic record of data). 
Written or electronic data of record must be entered on the electronic version of the CRF 
(e-CRF)  provided for that purpose. In some instances no prior written or electronic record of 
data may exist and data recorded directly on the e-CRF is considered source data. The site will be suitably trained on the use of the e-CRF and appropriate site personnel will be authorized to provide electronic signatures. The PI [INVESTIGATOR_430532].  All site entries will be made in a secured web site and the PI [INVESTIGATOR_430533] w the record 
for completeness. If corrections are necessary to the e-CRFs, the PI [INVESTIGATOR_430534] 
e-CRF and document the reason for change.  
 Completed e-CRFs will be submitted according to ADCS  protocols , and reviewed by [CONTACT_430617]. If necessary, data correction requests will be generated for 
resolution by [CONTACT_3452].  
   
ADC-041-EX   Page 64 of 78 
 
 Version 7.0: 18NOV2021 
   
 
 Audio / Visual Recording 
 
It is the s ite PI’s responsibility to ensure that any audio or visual recording conducted as part of 
the protocol are completed according to locally applicable laws and regulations. 
 
 Study Files and Patient Source Documents 
 Participant confidentiality is strictly held in trust by [CONTACT_473], research staff, and the 
ADCS and/or sponsoring  institution and their agents. This confidentiality is extended to cover 
testing of biological samples and genetic tests , and participant clinical information.  
 
The study protocol, documentation, data and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party, without prior written approval of the sponsoring institution. Authorized 
representatives of the sponsoring institution may inspect all required documents and records 
maintained by [CONTACT_093], including but not limited to, medical records (office, clinic or 
hospi[INVESTIGATOR_307]) and pharmacy records for participants . The study site will permit access to such 
records. Any data, specimens, forms, reports, video/audio recordings, and other records that leave the site will be identified only by a participant identification number (PID) to maintain confidentiality. All records will be kept in a locked file cabinet. All computer data entry will 
include only PI[INVESTIGATOR_29721] . Information will not be released without written permission of the participant, 
except as necessary for monitoring by [CONTACT_1201], the Intervention Oversight Team, the Food and 
Drug Adminis tration (FDA ), the NIA, and the Office for Human Research Protections (OHRP ). 
 18.0 ETHICS AND REGULATORY CONSIDERATIONS  
 
 Good Clinical Practice 
 This study will be conducted in accordance with Good Clinical Practice ( GCP ) guidelines, as 
defined by [CONTACT_5787] (ICH) Guideline, Topic E6, the [LOCATION_002] Code of Federal Regulations, Title 21, Part 50 (21CFR50) – Protection of Human 
Subjects and Part 56 – IRBs, HIPAA, State and Federal regulations and all other applicable 
local regulatory requirements and laws.    
 
Study personnel involved in conducting this study will be qualified by [CONTACT_8640], training and experience to perform their respective task(s)  in accordance with GCP.   
 No study document shall be destroyed without prior  written agreement between the ADCS and 
the investigator. Should the investigator wish to assign study records to another party or move them to another location, he/she may do so only with the prior written consent of the ADCS.  
  
ADC-041-EX   Page 65 of 78 
 
 Version 7.0: 18NOV2021 
   
 
 Institutional Review Boar d 
 
Each participating institution must provide for the review and approval of this protocol and the associated informed consent documents and recruitment material by [CONTACT_100834] . Any amendments to the protocol or consent materials must also be 
approved before they are placed into use. In the [LOCATION_002], only institutions holding a 
current US Federal -wide Assurance issued by [CONTACT_200315]. Refer to: 
http://www.hhs.gov/ohrp/assurances/ . 
 The investigator must obtain approval from the IRB for all subsequent ADCS protocol amendments and, when warranted, changes to the informed consent document. Protocol and informed consent form amendments can be made only with the prior approval of the ADCS.  The investigator may not implement any protocol deviation without prior notification to the ADCS and prior review and documented approval of the IRB, except where necessary to eliminate an 
immediate hazard to study participants, or  when change(s) involve only logistical or 
administrative aspects of the trial (ICH 4.5.4). The investigator shall notify the IRB of deviations 
from the protocol or SAEs occurring at the site, in accordance with local procedures.  
 
 Informed Consent and HIP AA Compliance 
 In obtaining and documenting informed consent, the investigator should comply with the applicable regulatory requirement(s), and should adhere to GCP and to the ethical principles that have their origin in the Declaration of Helsinki. Prior to the beginning of the trial, the investigator should have IRB approval of the written ICF  and any other written information to be 
provided to participants. Participants, their relatives, guardians, or authorized representatives and study partners will be given ample opportunity to inquire about the details of the study. Prior 
to a participant’s participation in the trial, the written ICF  should be signed and personally dated 
by [CONTACT_430618]. Participants should be provided a copy of the signed ICF.  The informed consent will not only cover consent for the trial itself, but also for the genetic 
research, biomarker studies, biological sample storage and brain imaging. The consent for storage will include consent to access stored data, biological samples, and imaging data for 
secondary analyses. Consent forms will specify that DNA and biomarker samples are for research purposes only; the tests on the DNA and biomarker samples are not diagnostic  in 
nature and participants will never receive results. MRI scan findings of clinical significance, determined by [CONTACT_360968], can  be shared with participants  per Study  Clinician discretion .  
 Consent forms will be developed by [CONTACT_430619] . 
The sample consent form provided to sites will include all of the required elements of informed 
consent required by [CONTACT_1622]. The sample consent form will be sent to participating sites where 
it should be tailored to include site-specific information to meet local IRB regulations. Each site PI, under the guidance of the local IRB, is responsible for ensuring that all applicable state laws 
are met with regards to judgment of competency and the consent form process. Each 
ADC-041-EX   Page 66 of 78 
 
 Version 7.0: 18NOV2021 
   
 participating site must submit a letter of IRB -approval and the approved consent form to 
Regulatory Affairs at the ADCS, along with other required regulatory records and essential 
documents in order to be approved to enroll participants into EXERT . During the first monitoring 
visit following participant enrollment, the ADCS clinical monitors will review the consent forms 
and verify that the proper signatures have been obtained.   
18.3.1 Participant Confidentiality | HIPAA  
 
Information about study participants will be kept confidential and managed according to the requirements of HIPAA. HIPAA regulations require a signed HIPAA Authorization informing the 
participant of the following:   
• What protected health information (PHI) will be collected from participants in this study  
• Who will have access to that information and why  
• Who will use or disclose that information 
• The rights of a research participant to revoke their authorization for use of their PHI 
 In the event that a participant revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability to use all information collected prior to the revocation of participant 
authorization. Each site PI, under the guidance of the local  IRB, is responsible for ensuring that 
all applicable HIPAA regulations and State laws are met.  
 Genetic Research and Storage of Genetic Material  
 The DNA is banked in locked freezers in the ADCS  Biomarker laboratory  at UCSD. Sample 
tubes are bar-coded and linked to PID  only and banked without personal identifiers . The 
presence of the sample is recorded into a computerized inventory database that is managed by [CONTACT_430620]-protected. 
 
Only DNA from consenting participants will be banked and used to facilitate future research on 
aging and dementia, particularly in the discovery of genetic polymorphisms that may influence 
risk of developi[INVESTIGATOR_201314]. Collection of DNA will permit ADCS investigators to probe candidate genetic polymorphisms as predictors of outcome in future studies. The samples will be stored by [CONTACT_360971]. If funding should lapse completely, the UCSD ADRC will provide responsible custodianship of the ADCS biospecimen bank.  
 
 Storage of Biospecimen Samples  
 All biospecimens banked for future AD biomarker research will be shipped to and stored by [CONTACT_360974]. Sample tubes are bar -coded and linked to PID only and 
banked without personal identifiers. The presence of the sample is recorded into a computerized inventory  database that is managed by [CONTACT_430621]-protected.  
 
ADC-041-EX   Page 67 of 78 
 
 Version 7.0: 18NOV2021 
   
 
 MRI Data Storage  
 
MRI scans will be labeled according to each site’s imaging machine capabilities using  PID and scanner specific series descriptions as detailed in the Technical Manual. All imaging 
data will be de-identified using participant identifiers as detailed in the Technical Manual and 
checked by [CONTACT_430622].  
 Inclusion of Children as Participants in Research Involving Human Subjects 
 Children will not be included. 
 
 Study Monitoring  
 
The ADCS clinical monitors are responsible for inspecting the e-CRFs  and source documents at 
regular intervals throughout the study to verify adherence to the protocol, completeness and 
accuracy of the data, and adherence to local regulations on the conduct of clinical research. An unblinded monitor will inspect documents pertaining to randomization, intervention implementation, and AEs. A blinded monitor will inspect all other source documents.   The monitoring visits must be conducted according to the applicable ICH and GCP guidelines to ensure protocol adherence, quality of data, drug accountability, compliance with regulatory requirements and continued adequacy of the investigational site and its facilities. The site investigator will cooperate in the monitoring process by [CONTACT_430623] e-CRFs, 
source and other necessary documents at the time of the monitoring visits. The site PI [INVESTIGATOR_430535]/her attention by [CONTACT_2037], and may be asked to meet in-person with the site monitor during monitoring visits.  
 19.0 A UDIT  
 
In accordance with ICH GCP, representatives of the ADCS and/or sponsor and/or regulatory agency m ay select this study for audit. The site PI [INVESTIGATOR_430536] -related regulatory documentation as outlined 
by [CONTACT_430624], sponsor, its designees, and/or regulatory agencies. Inspection of site facilities (e.g., pharmacy, laboratories , 
YMCAs ) to evaluate the trial conduct and compliance with the protocol may also occur.  
 
20.[ADDRESS_544661] be retained for a minimum of 7 years following 
primary publication of study  results. The ADCS will notify sites when retention of such 
documents is no longer required.  
  
ADC-041-EX   Page 68 of 78 
 
 Version 7.0: 18NOV2021 
   
 21.[ADDRESS_544662] of the PDs, the Protocol 
Committee, interested site PIs, and appropriate ADCS personnel . The publication committee will 
solicit input and assis tance from other investigators as appropriate and adhere to all ADCS 
Publications Policies.  
 
22.0 SHARING OF FINAL RES EARCH DATA  
 Data from this research will be shared with other researchers pursuant to the 02/26/2003 “ Final 
NIH Statement on Sharing Research D ata.” The ADCS grant contains a data sharing policy 
consistent with the goals of the NIH that also respects the rights of commercial partners. The NIH policy can be found at: 
http://grants.nih.gov/grants/guide/notice-files/NOT-OD -03-
032.html .  
 The NIH endorses the sharing of final research data to serve these and other important scientific goals. To protect participants’ rights and confidentiality, identifiers will be removed from the data before they are shared.  
 
  
ADC-041-EX   Page 69 of 78 
 
 Version 7.0: 18NOV2021 
   
 23.0 LITERATURE CITED  
 
1. Broe GA, Creasey H, Jorm AF, Bennett HP, Casey B, Waite LM, et al. Health habits and 
risk of cognitive impairment and dementia in old age: a prospective study on the effects 
of exercise, smoking and alcohol consumption. Aust N Z J Public Health. 1998;22(5):621-623. 
2. Rolland Y, Abellan van Kan G, Vellas B. Healthy brain aging: role of exercise and physical activity. Clin Geriatr Med. 2010;26(1):75-87. 
3. Laurin D, Verreault R, Lindsay J, MacPherson K, Rockwood K. Physical activity and risk 
of cognitive impairment and dementia in elderly persons. Arch Neurol. 2001;58:498-504. 
4. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology. 1995;45(6):1161-1168. 
5. Podewils LJ, Guallar E, Kuller LH, Fried LP, Lopez OL, Carlson M, et al. Physical 
activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health 
Cognition Study. Am J Epi[INVESTIGATOR_5541]. 2005;161(7):639-651. 
6. Albert MS, Jones K, Savage CR, Berkman L, Seeman T, Blazer D, et al. Predictors of 
cognitive change in older persons: MacArthur studies of successful aging. Psychol Aging. 1995;10(4):578-589. 
7. Geda YE, Roberts RO, Knopman DS, Christianson TJ, Pankratz VS, Ivnik RJ, et al. 
Physical exercise, aging, and mild cognitive impairment: a population-based study. Arch 
Neurol. 2010;67(1):80-86. 
8. Sumic A,  Michael YL, Carlson NE, Howieson DB, Kaye JA. Physical activity and the risk 
of dementia in oldest old. J Aging Health. 2007;19(2):242-259. 
9. Smith PJ, Blumenthal JA, Hoffman BM, Cooper H, Strauman TA, Welsh -Bohmer K, et al. 
Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosom Med. 2010;72(3):239-252. 
10. Colcombe SJ, Erickson KI, Scalf PE, Kim JS, Prakash R, McAuley E, et al. Aerobic exercise training increases brain volume in aging humans. J Gerontol A Biol Sci Med 
Sci. 2006;61(11):1166-1170. 
11. Voss MW, Prakash RS, Erickson KI, Basak C, Chaddock L, Kim JS, et al. Plasticity of 
brain networks in a randomized intervention trial of exercise training in older adults. 
Front Aging Neurosci. 2010;2. 
12. Burdette JH, Laurienti PJ, Espeland MA, Morgan A, Telesford Q, Vechlekar CD, et al. Using network science to evaluate exercise-associated brain changes in older adults. Front Aging Neurosci . 2010;2:23. 
13. Colcombe S, Erickson K, Raz N, Webb A, Cohen N, McAuley E, et al. Aerobic fitness 
reduces brain tissue loss in aging humans. J of Gerontol: Med Sci. 2003;58A(2):176-180. 
14. Burns JM, Cronk BB, Anderson HS, Donnelly JE, Thomas GP, Harsha A, et al. Cardiorespi[INVESTIGATOR_430537]. Neurology. 
2008;71(3):210-216. 
15. Makizako H, Shimada H, Doi T, Yoshida D, Ito K, Kato T, et al. The association between decline in physical functioning and atrophy of medial temporal areas in community -
dwelling older adults with amnestic and nonamnestic mild cognitive impairment. Arch Phys Med Rehabil. 2011;92(12):1992-1999. 
ADC-041-EX   Page 70 of 78 
 
 Version 7.0: 18NOV2021 
   
 16. Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, et al. 
Effects of aerobic exercise on mild cognitive impairment: A controlled trial . Arch Neurol. 
2010;67(1):1-9. 
17. Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J, et al. 
Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. Jama. 2008;300(9):1027-1037. 
18. Baker LD, Skinner J, Saucedo-Hernandez H, Sink KM, Wilson V, Craft S, et al. Therapeutic effects of high intensity aerobic exercise in adults with two strikes against 
them: MCI and prediabetes. In: Wake Forest University Health Sciences; s ubmitted. 
19. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. 
American College of Sports Medicine position stand. Quantity and quality of exercise for developi[INVESTIGATOR_104618], musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 
2011;43(7):1334-1359. 
20. Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, et al. 
Aerobic exercise improves cognition for older adul ts wit h glucose intolerance, a risk 
factor for Alzheimer's disease. J Alzheimers Dis. 2010;22(2):569-579. 
21. Tolppanen AM, Solomon A, Kulmala J, Kareholt I, Ngandu T, Rusanen M, et al. Leisure-time physical activity from mid- to late life, body mass index, and risk of dementia. 
Alzheimers Dement. 2014. 
22. Liang KY, Mintun MA, Fagan AM, Goate AM, Bugg JM, Holtzman DM, et al. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol. 2010;68(3):311-318. 
23. Pescatello LS. Physical  activity, cardiometabolic health and older adults: recent findings. 
Sports Med. 1999;28(5):315-323. 
24. Holland D, Brewer JB, Hagler DJ, Fennema-Notestine C, Dale AM. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Aca d Sci U S 
A. 2009;106(49):[ZIP_CODE]-[ZIP_CODE]. 
25. Jack CR, Jr., Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, et al. Evidence for Ordering of Alzheimer Disease Biomarkers. Arch Neurol.  2011. 
26. Okonkwo OC, Mielke MM, Griffith HR, Moghekar AR, O'Brien RJ, Shaw LM, et al. Cerebrospi[INVESTIGATOR_430538]. Arch Neurol. 2011;68(1):113-119. 
27. Shaw LM, Vanderstichele H, Knapik -Czajka M, Figurski M, Coart E, Blennow K, et al . 
Qualification of the analytical and clinical performance of CSF biomarker analyses in 
ADNI. Acta Neuropathol. 2011;121(5):597-609. 
28. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, et al. Cerebrospi[INVESTIGATOR_430539]. Arch Neurol. 2009;66(5):638-645. 
29. Jack CR, Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. 
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. 
Lancet Neurol . 2010;9(1):119-128. 
30. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, et al. Decreased 
cerebrospi[INVESTIGATOR_430540](42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65(2):176-183. 
31. Erickson KI, Voss MW, P rakash RS, Basak C, Szabo A, Chaddock L, et al. Exercise 
training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. 2011;108(7):3017-3022. 
ADC-041-EX   Page 71 of 78 
 
 Version 7.0: 18NOV2021 
   
 32. Olson L, Humpel C. Growth factors and cytokines/chemokines as surrogate biomarkers 
in cerebr ospi[INVESTIGATOR_430541]'s disease and mild cognitive 
impairment. Exp Gerontol. 2010;45(1):41-46. 
33. Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, et al. Visinin-like protein-1: diagnostic and prognostic biomarker i n Alzheimer disease. Ann Neurol. 
2011;70(2):274-285. 
34. Li G, Peskind ER, Millard SP, Chi P, Sokal I, Yu CE, et al. Cerebrospi[INVESTIGATOR_430542]-derived neurotrophic factor and cognitive function in non-
demented subjects. PLoS One . 2009;4(5):e5424. 
35. Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ. Cerebrospi[INVESTIGATOR_430543]-demented patients with Parkinson's disease. Parkinsonism Relat Disord. 2011;17(1):61-64. 
36. Nichol KE, Po on WW, Parachikova AI, Cribbs DH, Glabe CG, Cotman CW. Exercise 
alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation. 2008;5:13. 
37. Garcia -Mesa Y, Pareja-G aleano H, Bonet-Costa V, Revilla S, Gomez -Cabrera MC, 
Gambini J, et al. Physical exercise neuroprotects ovariectomized 3xTg- AD mice through 
BDNF mechanisms. Psychoneuroendocrinology. 2014;45:154-166. 
38. Shen L, Kim S, Qi Y, Inlow M, Swaminathan S, Nho K, et al. Identifying Neuroimaging and Proteomic Biomarkers for MCI and AD via the Elastic Net. Lect Notes Comput Sci. 2011;7012:27-34. 
39. Thambisetty M, Tripaldi R, Riddoch-Contreras J, Hye A, An Y, Campbell J, et al. Proteome-based plasma markers of brain amyloid-beta deposition in non -demented 
older individuals. J Alzheimers Dis.  2010;22(4):1099-1109. 
40. Craig -Schapi[INVESTIGATOR_2152] R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL -40: a 
novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry. 
2010;68(10):903-912. 
41. Perrin RJ, Craig -Schapi[INVESTIGATOR_2152] R, Malone JP, Shah AR, Gilmore P, Davis AE, et al. 
Identification and validation of novel cerebrospi[INVESTIGATOR_430544]'s disease. PLoS One . 2011;6(1):e16032. 
42. Bartres-Faz D, Junque C, Clemente IC, Lopez -Alomar A, Valveny N, Lopez -Guillen A, et 
al. Angiotensin I converting enzyme polymorphism in humans with age-associated 
memory impairment: relationship with cognitive performance. Neurosci Lett. 2000;290(3):177-180. 
43. Richard F, Berr C, Amant C, Helbecque N, Amouyel P, Alperovitch A. Effect of the angiotensin I-c onverting enzyme I/D polymorphism on cognitive decline. The EVA Study 
Group. Neurobiol Aging. 2000;21(1):75-80. 
44. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10(5):333-344. 
45. Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S, et al. Angiotensin- converting enzyme (ACE) levels and activity in Alzheimer's disease, and 
relationship of perivascular ACE -[ADDRESS_544663] 
Neurobiol. 2008;34(2):181-193. 
46. Zhang Z, Deng L, Bai F, Shi Y, Yu H, Yuan Y, et al. ACE I/D polymorphism affects cognitive function and gray -matter volume in amnestic mild cognitive impairment. Behav 
Brain Res. 2011;218(1):114-120. 
47. Hajjar I, Kritchevsky S, Newman AB, Li R, Yaffe K, Simonsick EM, et al. Renin angiotensin system gene polymorphisms modify angiotensin- converting enzyme 
ADC-041-EX   Page 72 of 78 
 
 Version 7.0: 18NOV2021 
   
 inhibitors' effect on cognitive function: the health, aging and body composition study. J 
Am Geriatr Soc. 2010;58(6):1035-1042. 
48. Bour AM, Rasquin SM, Baars L, van Boxtel MP, Visser PJ, Limburg M, et al. The effect 
of the APOE -epsilon4 allele and ACE -I/D polymorphism on cogni tion during a two-year 
follow -up in first-ever stroke patients. Dement Geriatr Cogn Disord. 2010;29(6):534-542. 
49. Jacobs DM, Thomas RG, Salmon DP, Jin S, Feldman HH, Cotman CW, et al. 
Development of a novel cognitive composite outcome to assess therapeutic effects of exercise in the EXERT trial for adults with MCI: The ADAS -Cog-Exec. Alzheimers 
Dement (N Y). 2020;6(1):e12059. 
50. Colcombe S, Kramer A. Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychological Science. 2003;14(2):125-130. 
51. Kramer A, Hahn S, Cohen N, Banich M, McAuley E, Harrison C, et al. Ageing, fitness and neurocognitive function. Nature. 1999;400(29):418-419. 
52. O'Brien JL, O'Keefe KM, LaViolette PS, DeLuca AN, Blacker D, Dickerson BC, et al . 
Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology. 2010;74(24):1969-1976. 
53. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI, and AD subj ects: predicting future clinical change. 
Neurology. 2009;73(4):294-301. 
54. Jack CR, Jr., Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology. 2003;60(2):253-260. 
55. Holland D, Brewer JB, Hagler DJ, Fennema-Notestine C, Dale AM. Subregional 
neuroanatomical change as a biomarker for Alzheimer's disease. Proceedings of the 
National Academy of Sciences of the [LOCATION_002] of America. 2009;106(49):[ZIP_CODE]-
[ZIP_CODE]. 
56. Spi[INVESTIGATOR_378763], Gamaldo AA, An Y, Wu MN, Simonsick EM, Bilgel M, et al. Self-reported 
Sleep and beta-Amyloid Deposition in Community -Dwelling Older Adults. JAMA 
neurology. 2013. 
57. Fredrickson J, Maruff P, Woodward M, Moore L, Fredrickson A, Sach J, et al. Evaluation 
of the usability of a brief computerized cognitive screening test in older people for epi[INVESTIGATOR_9037]. Neuroepi[INVESTIGATOR_623]. 2010;34(2):65-75. 
58. McDowell I, Kristjansson B, Hill GB, Hebert R. Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini -Mental State Exam (3MS) 
compared. J Clin Epi[INVESTIGATOR_5541]. 1997;50(4):377-383. 
59. Yaffe K, Falvey CM, Hoang T. Connections between sleep and cognition in older adults. Lancet Neurol. 2014;13(10):1017-1028. 
60. Rolls A,  Colas D, Adamantidis A, Carter M, Lanre-Amos T, Heller HC, et al. Optogenetic 
disruption of sleep continuity impairs memory consolidation. Proc Natl Acad Sci U S A. 2011;108(32):[ZIP_CODE]-[ZIP_CODE]. 
61. Mansikkamaki K, Raitanen J, Nygard CH, Heinonen R, Mikkola T, EijaTomas, et al. 
Sleep quality and aerobic training among menopausal women--a randomized controlled trial. Maturitas. 2012;72(4):339-345. 
62. Reid KJ, Baron KG, Lu B, Naylor E, Wolfe L, Zee PC. Aerobic exercise improves self-reported sleep and quality of life in older adults with insomnia. Sleep medicine. 2010;11(9):934-940. 
63. Santos RV, Viana VA, Boscolo RA, Marques VG, Santana MG, Lira FS, et al. Moderate exercise training modulates cytokine profile and sleep in elderly people. Cytokine. 2012;60(3):731-735. 
ADC-041-EX   Page 73 of 78 
 
 Version 7.0: 18NOV2021 
   
 64. Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS, Bennett DA. Total daily physical 
activity and the risk of AD and cognitive decline in older adults. Neurology. 2012;78(17):1323-1329. 
65. Garland T, Jr., Schutz H, Chappell MA, Keeney BK, Meek TH,  Copes LE, et al. The 
biological control of voluntary exercise, spontaneous physical activity and daily energy expenditure in relation to obesity: human and rodent perspectives. The Journal of experimental biology.  2011;214(Pt 2):206-229. 
66. Turner RS. Bi omarkers of Alzheimer's disease and mild cognitive impairment: are we 
there yet? Experimental neurology. 2003;183(1):7-10. 
67. Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, et al. Cerebrospi[INVESTIGATOR_430545]'s disease. Ann Neurol. 
2005;57(5):721-729. 
68. Smith JC, Nielson KA, Woodard JL, Seidenberg M, Durgerian S, Hazlett KE, et al. 
Physical activity reduces hippocampal atrophy in elders at genetic risk for Alzheimer's 
disease. Front Aging Neurosci. 2014;6:61. 
69. US Department of Health and Human Services. Physical Activity Guidelines Advisory Committee Report, 2008 [Internet]. In. Washington DC2008. 
70. Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The incidence of primary cardiac arrest during vigorous exercise. N Engl J Med. 1984;311(14):874-877. 
71. Pollock ML, Wilmore JH. Exercise in health and disease: evaluation and prescription for prevention and rehabilitation. 2nd ed. Philadelphia: W. B. Saunders; 1990. 
72. Pollack ML. Prescribing exercise for fitness and adherence. In: Dishman RK, ed. 
Exercise adherence: its impact on public health.  Champaign, IL: Human Kinetics Books; 
1998:259-277. 
73. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc.  
2007;39(8):1423-1434. 
74. Pollock ML, Carroll JF, Graves JE, Leggett SH, Braith RW, Limacher M, et al. Injuries  
and adherence to walk/jog and resistance training programs in the elderly. Med Sci 
Sports Exerc. 1991;23(10):1194-1200. 
75. Pollock ML, Gettman LR, Milesis CA, Bah MD, Durstine L, Johnson RB. Effects of 
frequency and duration of training on attrition and incidence of injury. Med Sci Sports. 
1977;9(1):31-36. 
76. Gill TM, DiPi[INVESTIGATOR_52468] L, Krumholz HM. Role of exercise stress testing and safety monitoring 
for older persons starting an exercise program. Jama. 2000;284(3):342-349. 
77. Fielding RA, Rejeski WJ, Blair S, Chu rch T, Espeland MA, Gill TM, et al. The Lifestyle 
Interventions and Independence for Elders Study: design and methods. J Gerontol  A 
Biol Sci Med Sci.  2011;66(11):1226-1237. 
78. Pahor M, Blair SN, Espeland M, Fielding R, Gill TM, Guralnik JM, et al. E ffects  of a 
physical activity intervention on measures of physical performance: Results of the 
lifestyle interventions and independence for Elders Pi[INVESTIGATOR_2268] (LIFE -P) study. J Gerontol A 
Biol Sci Med Sci.  2006;61(11):1157-1165. 
79. Amariglio RE, Frishe K, Olson LE, W adsworth LP, Lorius N, Sperling RA, et al. 
Validation of the Face Name [CONTACT_430634]. Journal of clinical and experimental neuropsychology. 2012;34(6):580-587. 
80. Peskind ER, Riekse R, Quinn JF, Kaye J, Clark CM, Farlow MR, et al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord.  
2005;19(4):220-225. 
ADC-041-EX   Page 74 of 78 
 
 Version 7.0: 18NOV2021 
   
 81. Armitage P, Berry G. Statistical methods in medical research. 3rd ed: Blackwell Scientific 
Publications; 1994. 
82. Nickl as BJ, Brinkley TE. Exercise training as a treatment for chronic inflammation in the 
elderly. Exerc Sport Sci Rev.  2009;37(4):165-170. 
83. Williamson JD, Espeland M, Kritchevsky SB, Newman AB, King AC, Pahor M, et al. 
Changes in cognitive function in a randomized trial of physical activity: results of the 
lifestyle interventions and independence for elders pi[INVESTIGATOR_799]. J Gerontol A Biol Sci Med Sci. 2009;64(6):688-694. 
84. Baker L. Effects of aerobic exercise on cognition for memory -impaired older adults wi th 
prediabetes. In. Veterans Affairs Puget Sound Healthcare System: American Diabetes 
Association; 2010. 
85. Nicklas BJ, Hsu FC, Brinkley TJ, Church T, Goodpaster BH, Kritchevsky SB, et al. Exercise training and plasma C-reactive protein and interleukin -6 in elderly people. J Am 
Geriatr Soc. 2008;56(11):2045-2052. 
86. Pahor M, Guralnik JM, Ambrosius WT, Blair S, Bonds DE, Church TS, et al. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study  randomized clinical trial. Jama. 2014;311(23):2387-2396. 
87. Mayer CJ, Steinman L, Williams B, Topolski TD, LoGerfo J. Developi[INVESTIGATOR_007] a Telephone Assessment of Physical Activity (TAPA) questionnaire for older adults. Preventing 
chronic disease. 2008;5(1):A24. 
88. T eng EL, Chui HC. The Modified Mini -Mental State (3MS) examination. The Journal of 
clinical psychiatry. 1987;48(8):314-318. 
89. Cahn DA, Salmon DP, Monsch AU, Butters N, Wiederholt WC, Corey -Bloom J, et al. 
Screening for dementia of the Alzheimer type in the community: The utility of the Clock 
Drawing Test. Arch Clin Neuropsychol. 1996;11(6):529-539. 
90. Wechsler D. WMS -R Wechsler Memory Scale - Revised Manual. [LOCATION_001]: The 
Psychological Corporation, Harcourt Brace Jovanovich, Inc.; 1987. 
91. Rey A. L'examen clinique en psychologie. Paris: Presses Universitaires de [LOCATION_009]; 
1964. 
92. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. American 
Journal of Psychiatry. 1984;141(11):1356-1364. 
93. Hamel R, Kohler S, Sistermans N, Koene T, Pi[INVESTIGATOR_430546] Y, van der Flier W, et al. The 
trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C -MCI study. Psychological medicine. 2014:1-11. 
94. Zelazo PD, Anderson JE, Richler J, Wallner -Allen K, Beaumont JL, Conway KP, et al. 
NIH Toolbox Cognition Battery (CB): validation of executive function measures in adults. Journal of the International Neuropsychological Society : JINS. 2014;20(6):620-629. 
95. Pi[INVESTIGATOR_41279], Cohen H, Snyder PJ. Spatial learning efficiency and error monitoring in normal aging: an investigation using a novel hidden maze learning test. Archives of 
clinical neuropsychology : the official journal of the National Academy of 
Neuropsychologists.  2007;22(2):235-245. 
96. Snyder PJ, Bednar M M, Cro mer JR, Maruff P. Reversal of scopolamine-induced deficits 
with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimers Dement. 
2005;1(2):126-135. 
97. Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent 
component analysis. Journal of Neuroscience. 2006;26(40):[ZIP_CODE]-[ZIP_CODE]. 
ADC-041-EX   Page 75 of 78 
 
 Version 7.0: 18NOV2021 
   
 98. Miller SL , Celone K, DePeau K, Diamond E, Dickerson BC, Rentz D, et al. Age-related 
memory impair ment associated with loss of parietal deactivation but preserved 
hippocampal activation. ProcNatlAcadSci[LOCATION_003]. 2008;105(6):2181-2186. 
99. Sperling RA, Chua E, Cocchiarella A, Rand-Giovannetti E, Poldrack R, Schacter DL, et 
al. Putting names to faces: s uccess ful encoding of associative memories activates the 
anterior hippocampal formation. Neuroimage. 2003;20(2):1400-1410. 
100. Hayes SM, Alosco ML, Hayes JP, Cadden M, Peterson KM, Allsup K, et al. Physical Activity Is Positively Associated with Epi[INVESTIGATOR_430547]. Journal of the 
International Neuropsychological Society : JINS. 2015;21(10):780-790. 
101. Bakker A, Kirwan CB, Miller M, Stark CE. Pattern separation in the human hippocampal CA3 and dentate gyrus. Science. 2008;319(5870):1640-1642. 
102. Stark SM, Yassa MA, Stark CE. Individual differences in spatial pattern separation 
performance associated with healthy aging in humans. Learn Mem. 2010;17(6):284-288. 
103. Yassa MA, Mattfeld AT, Stark SM, Stark CE. Age-related memory deficits linked to circuit-specific disruptions in the hippocampus. Proc Natl Acad Sci U S A. 
2011;108(21):8873-8878. 
104. Yassa MA, Stark SM, Bakker A, Albert MS, Gallagher M, Stark CE. High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients wit h 
amnestic Mild Cognitive Impairment. Neuroimage. 2010;51(3):1242-1252. 
105. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74(3):467-474. 
106. Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, et al. Nicotine treatment of mild cognitive impairment: a 6-month double- blind pi[INVESTIGATOR_29833]. Neurology. 
2012;78(2):91-101. 
107. Darby [CONTACT_24226], Brodtmann A, Pi[INVESTIGATOR_41279], Fredrickson J, Woodward M, Villemagne VL, et 
al. Epi[INVESTIGATOR_430548] -Dwelling 
Older Adults. J Alzheimers Dis. 2011;27(3):627-637. 
108. Lim YY, Ellis KA, Pi[INVESTIGATOR_41279], Ames D, Darby D, Harrington K, et al. Stron ger effect of 
amyloid load than APOE genotype on cognitive decline in healthy older adults. 
Neurology. 2012;79(16):1645-1652. 
109. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, et al. Mild 
cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61(1):59-66. 
110. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory 
to assess activities of daily living for clinical trials in Alzheimer's  disease. The 
Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;[ADDRESS_544664] 
2:S33-39. 
111. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48([ADDRESS_544665] 6):S10-16. 
112. Saykin AJ,  Wishart HA, Rabin LA, Santulli RB, Flashman LA, West JD, et al. Older 
adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology. 2006;67(5):834-842. 
113. Snowdon J. Validity of the Geriatric Depression Scale. J Am Geri atr Soc. 
1990;38(6):722-723. 
114. McHorney CA, Ware JE, Jr., Raczek AE. The MOS 36-Item Short-Form Health Survey 
(SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental 
health constructs. Med Care. 1993;31(3):247-263. 
ADC-041-EX   Page 76 of 78 
 
 Version 7.0: 18NOV2021 
   
 115. Devlin NJ, Krabbe PF. The development of new research methods for the valuation of 
EQ-5D -5L. The European journal of health economics : HEPAC : health economics in 
prevention and care. 2013;[ADDRESS_544666] 1:S1-3. 
116. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep medicine. 2001;2(4):297-307. 
117. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980;7(5):486-488. 
118. Duncan BL, Miller SD, Wampold BE, Hubble MA. The heart and soul of change: 
Delivering what works in therapy. 2 ed: American Psychological Association; 2010. 
119. Miller SD, Duncan BL, Sorrell R, Brown GS. The partners for change outcome management system. Journal of clinical psychology. 2005;61(2):199-208. 
120. Arnold JB, Liow JS, Schaper KA, Stern JJ, Sled JG, Shattuck DW, et al. Qualitativ e and 
quantitative evaluation of six algorithms for correcting intensity nonuniformity effects . 
Neuroimage. 2001;13(5):931-943. 
121. Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R, et al. Reliability in multi -site structural MRI studies: effects of gradient non-linearity correction on phantom 
and human data. Neuroimage. 2006;30(2):436-443. 
122. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17(1):87-97. 
123. Simonsick EM, Fan E, Fleg JL. Estimating cardiorespi[INVESTIGATOR_363472] -functioning 
older adults: treadmill validation of the long distance corridor walk. J Am Geriatr Soc.  
2006;54(1):127-132. 
124. American College of Sports Medicine Position Stand. Exercise and physical activity for older adults. Med Sci Sports Exerc. 1998;30(6):992-1008. 
125. Furberg CD, Manolio TA, Psaty BM, Bild DE, Borhani NO, Newman A, et al. Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group. Am J Cardiol. 1992;69(16):1329-1335. 
126. Exercise and the heart. 4th ed. Philadelphia, PA: WB Saunders; 2000.  
  
ADC-041-EX   Page 77 of 78 
 
 Version 7.0: 18NOV2021 
   
 APPENDIX 1: SCHEDULE  OF EVENTS  
Visit  Number  0 1 2 3 4 5 
Visit  Name / Month  Screen  I Screen  II Baseline  6 121 18 
Visit Window (w eeks)     +/- 2 +/- 2 +/- 2 
Brief Informed Consent for Screen I 
(screening for Screen II)  X      
Informed Consent for Enrollment, HIPAA   X     
EXERT TAPA  (to confirm sedentary 
status)  X      
Review Inclusion & Exclusion Criteria  X X     
Demographics  X X     
Medical History  X X     
Medication Review  X X X X X X 
Brief Physical Exam   X  X X X 
Vital Signs   X X X X X 
Height   X     
Weight   X X X X X 
Brief Neurological Exam   X  X X X 
Modified Hachinski   X     
Fasting Clinical Blood Labs   X   X X 
Blood Col lection for ApoE Genotypi[INVESTIGATOR_007] , & 
DNA Banking   X     
Fasting Blood Collection for Banking    X X X X 
AE Monitoring at Clinic    X X X X 
12-Lead Resting ECG   X     
3MSE/MMSE   X   X  
Logical Memory I and II   X     
Auditory Verbal Learning Test   X     
ADAS -Cog13    X X X X 
Trail-Making Test, DSST , Category and 
Letter Word Fluency     
X  
X  
X  
X 
Computer Tests: NIH Toolbox (Flanker, 
DCCS ), Cogstate ( DET, IDN, OCL, OBK, 
GMLT , FNAME,  BPSO )    
X  
X  
X  
X 
CDR   X  X X X 
ADCS -ADL-MCI, BRIEF -A, NPI (staff -
administ ered questionnaires)     
X  
X  
X  
X 
GDS (self -administered questionnaire)   X     
Cognitive Change Index 
(self-administered questionnaire)   X  X X X 
SF-36, EQ5D (self -administered)    X X X X 
Research Satisfaction Survey 
(self-administered)    X X X X 
Study Partner Self -Assessment 
Questionnaire2   X X X X 
[ADDRESS_544667]   X  X X X 
Structural/Functional MRI3  X   X  
LP for CSF Collection and Banking4   X  X  
ADC-041-EX   Page 78 of 78 
 
 Version 7.0: 18NOV2021 
   
 Visit  Number  0 1 2 3 4 5 
Visit  Name / Month  Screen  I Screen  II Baseline  6 121 18 
Visit Window (w eeks)     +/- 2 +/- 2 +/- [ADDRESS_544668] Battery in Heart Rate Monitor     X X X 
Dispense Physical Activity Log s   X X X  
Retrieve/Review Physical Activity Log s5   X X X X 
Actigraphy Recording Initialization 
(dispense device)6  X  X X X 
Actigraphy Device Retrieval (10 days 
later)6   X X X X 
Telephone Call to Participant by [CONTACT_430625] (query AEs, obtain 
medication updates)7    
X  
X  
X  
 
Trainer -Supervised Exercise Sessions8   X X X  
Trainer -Administered Rating of 
Perceived Exertion9   X X X  
Trainer -Administered AE Checklist10   X X X  
Randomization   X    
Treatment Blindi ng Questionnaire      X X 
Provide Study Close -Out Materials       X 
 
1   Following Month 12 assessment, participants continue with their assigned exercise program but  without 
supervision in Months 13 -18 
2  The Study Partner Self -Assessment Questionnaire is comprised of the SF-36, the Pi[INVESTIGATOR_8326], the Insomnia Severity Index , the EQ5D , and questions about healthcare utilization  
3   Screening MRI to be conducted following site PI [INVESTIGATOR_430549]/ex clusion criteria; fMRI sequences added to protocol for approved sites  
4   To be completed for fasting participants who agree to LP at Baseline and Month 12  
5   Logs reviewed by [CONTACT_430626] (in months 1 -12), and by [CONTACT_430627]  (months 1- 18) to identify potential adherence  issues  
6   See Section 9.0 for visit-specific i nstructions  
7   Telephone call to be completed monthly  (months 1 -18) 
8   Supervision provided by [CONTACT_3449] -certified YMCA Trainers , beginning after randomization through Month 
 12; data collected include type of exercise completed, exercise duration, HR, RPE, and other 
 intervention -specific details (e.g., body parts stretched, treadmill speed and grade)  
9  Rating scale administered as part of every supervised exercise session (months 1- 12) to assess effort 
 and estimate exercise intensity  
10Administered once per week  by [CONTACT_430628] 7 days ; faxed to clinic for triage and data entry  within 24 hours of the session  
 